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Oncolytic virotherapy is a promising avenue of cancer therapy. It is a 
therapeutic approach to cancer treatment that utilizes native or genetically 
modified human viruses that selectively replicate in tumor cells or 
nonhuman viruses that are naturally oncotropic and preferentially 
replicate in tumor cells, displaying minimal adverse effects in normal 
healthy cells. To date, a wide variety of viruses have been evaluated for 
their oncolytic potential, including DNA viruses as well as RNA viruses. 
CpHV-1 is a species-specific herpesvirus closely related to Bovine 
herpesvirus type 1 (BHV-1). Previuos works have demonstrated that 
CpHV 1 is able to induce apoptosis in goat peripheral blood mononuclear 
cells, moreover we have investigated on the pro apoptotic potential of 
CpHV 1 in Madin Darby bovine kidney cells, evaluating apoptotic 
profiles like chromatin condensation and DNA laddering. Recently, the 
intracellular pathway by which CpHV 1 is able to induce apoptosis has 
been characterized in more details, by analyzing the gene expression 
response during the apoptotic phase of CpHV 1 infection in a murine 
neuroblastoma cell line (Neuro 2a). Thus, the aim of the present research 
was to investigate the ability of CpHV-1 to replicate, cause cell death and 
affect cellular viability in a panel of human cancer cells lines. Human 
breast adenocarcinoma (MDA-MB-468), Human cervical 
adenocarcinoma (HeLa), Human osteosarcoma (U2OS), Human prostatic 
adenocarcinoma (PC3), Human lung carcinoma (A549) and Chronic 
Myelogenous Leukemia (K562) cell lines were used. Madin Darby bovine 
kidney (MDBK) cell line was used as control. In a first series of 
experiment we have analyzed the effect of CpHV‐1 infection on cell 
viability by means of the MTT assay at different time post infection (p.i.) 
Abstract  
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and several multiplicity of infection (MOI). All cell lines, except K562 
cells, showed a marked cytopatic effect (CPE), demonstrating an 
oncolytic potential of CpHV-1 in tested human cancer cells. The 
reduction of cells viability was associated with significant levels of viral 
production as assayed by TCID50 after 24 h p.i. for MDBK, MDA-
MD468, A549, U2OS, and after 48 h p.i. for PC3, HeLa and K562 cell 
lines. Then, we investigated virus induced cytotoxicity, viability, and 
apoptosis within a single assay well, by using the ApoTox‐Glo Triplex 
assay. Analysis of virus‐infected cells revealed activation of caspase‐3, a 
marker of apoptosis at 24 h post‐infection. Analysis of virus‐infected, 
cells by western blot assay, revealed activation of caspase‐3 and cleaved 
caspase 3 at 24 h p. i. in MDBK, PC3, MDA-MD-468 and U2OS cell 
lines. Our findings demonstrate the effect of CpHV‐1 infection in 
neoplastic cell lines in terms of caspase activation and apoptosis 
modulation, thus CpHV-1 could be a novel candidate oncolytic viru
  19 
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1. Oncolytic virotherapy 
Neoplastic diseases represent one of the most common causes of death 
among humans and pets. In 2006, the World Health Organization reported 
cancer as the second cause of death in developed countries and the third 
cause in the worldwide (Lopez et al.; 2006). Numerous risk factors 
responsible for cancer development have been characterized, such as 
smoking, obesity, unhealthy diet, chronic infection or exposure to natural 
or chemical carcinogens. Some inherited genetic factors can also 
predispose to cancer development. Altough treatments for the neoplastic 
disease have significantly improved, conventional therapeutic options 
often remain insufficient and unsatisfactory; therefore, new and innovative 
strategies and approaches are higly needed. Oncolytic viruses (OVs) are 
viral strains that can infected and kill malignant cell (oncolysis), leaving 
surrounding healthy cells unharmed. In addition to direct cytotoxic 
activity, OVs enage and amplify host immune responses, leading to the 
distruction of residual malignant cells and establishment of lasting 
antitumor immunity. Oncolysis can be either a natural property of the virus 
(naturally occurring OVs, for example reovirus) or a consequence of 
manipulation of the viral genome (genetically engineered OVs, for 
example adenovirus) and renders oncolytic virotherapy (OVT) a potential 
therapeutic modality in cancer treatment. OVT has been studied for the last 
century; initial interest in the use of viruses to treat cancer dates to 
observations made in the early 1900s of tumor regression in the context of 
natural viral infection. One of the first case report of a drammatic 
regression of cervical cancer in a patient receiving the Pasteur-Roux live 
   Oncolytic virotherapy  
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attenuated rabies vaccine, was presented in 1910 (Sinkovics et al.; 2008). 
In 1940s, human studies with different types of viruses were launched 
(Hoster et al.; 1949).  The era of modern oncolytic virotherapy started in 
the early 1990s, when a genetically modified, live-attenuated, thymidine 
kinase (TK)-negative herpes simplex virus (HSV) strain was locally 
injected into human glioma kenograft models, showing positive results 
(Martuza et al.; 1991). Recent advances in genetic engineering technology 
spurred a renewed interest in OVT, to enhance the safety and efficacy of 
oncolytic vectors. Today, IMLYGIC™ (T-VEC/Talimogene 
Laherparepvec), a genetically engineered HSV, is the first OV approved by 
the FDA for use in the United States and the European Union for patients 
with locally advanced or non-resectable melanoma (FDA, 2015; EMA, 
2015). Numerous clinical trials have demonstrated sinergy between OVT 
and other standard and emerging anticancer therapy (Khuri et al.; 2000; 
Karapangiotou et al.; 2012). Combination treatment, particularly with 
immune-modulating therapies, remains a promising field of research. 
Activation of the host immune system is a crucial component of OV-
mediated tumor destruction; optimization of viral replication and 
propagation as well as the generation of anticancer immunity remain a 
significant challenge facing OVT.  With a better understanding of the 
complex immunological interactions between OVs, tumor cells and the 
host immune system, the next generation of OVs will be poised to exploit 
the full immunotherapeutic potential of OVT.  
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1.1 Oncolytic viruses: brief history of oncolytic viruses 
Oncolytic viruses show the natural propensity to infect malignant cells. 
Cancer cells are resisted to apoptosis and growth suppression, evade 
immune-mediated destruction and proliferate indefinitely; similar 
characteristics are also referable to viral replication (Choi et al.; 2016). 
Moreover, many tumors develop defects in cellular antiviral response 
pathways, like type I interferon (IFN) signaling, rendering these cells more 
susceptible to viral infection (Nguyen et al.; 2008). OVs have the capacity 
to selectively replicate in cancer cells, causing antitumor effects through a 
variety of mechanisms, including direct lysis of infected cells and immune-
mediated destruction of both infected and non-infected cells (Ito et al.; 
2006; Boozari et al.; 2010). Although viruses have been used as 
therapeutic agents in the form of vaccines since the late 1700s (Pasteur, 
1885; Willis et al.; 1997), their potential application as cancer therapy had 
not been explored until the early 1900s (Bierman et al.; 1953). In the most 
often-cited report, G. Dock decribes the case of a 42-years old woman 
suffering from leukemia who showed remission after infection with 
presumed influenza (Dock; 1904). In another case, a four-years old boy 
with leukemia showed a remarkable remission after acquiring chickenpox 
(Bierman et al.; 1953), but after a one-month remission, his leukemia 
relapsed and progressed rapidly to death. Several early landmark human 
clinical trials demonstrated both the potential of viral therapy as a cancer 
treatment, as well as its alarming side effects (Asada 1974; Southam et al.; 
1952). Altough some patients experienced short-lived clinical remission of 
cancer, a notable proprortion either died from the side effects of the viral 
therapy like hepatitis or fatal neuroencephalitis, or had the brief remission 
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that were reversed by a strong anamnestic response by the patient’s 
immune system, leading to continued cancer progression and death for the 
primary disease (Asada; 1974). These observations suggested that 
occurring viruses possessed an innate ability to kill cancer, but in order to 
harness the potential of oncolytic viral therapy, modifications would be 
requie to both improve cancer cell selectivity, safety and efficacy of 
virotherapy. Following a series of disappointing clinical trials, interest in 
OVs declined in the 1970-80s until the development of genetic engineering 
in the 1990s made possibile to improve selectivity and decrease toxicity. In 
another landmark study, Martuza et coll. reported that treatment with a 
thymidine kinase (TK)-mutated HSV-1 could reduce glioma in mice brains 
with low neurotoxicity (Martuza et al.; 1991).  
ONYX -015 was the first virus to enter Phase I clinical trials in 1996 and 
the adenovirus mutant H101 became the world’s first OV approvated for 
cancer treatment in 2005 (Garber et al.; 2006). Following a Phase III trial 
showing improved durable response rate for the intralesional treatment of 
melanoma, T-VEC became the first oncolytic virus approved by the FDA 
in October 2015 (Andtbacka et al.; 2015). 
 
1.2 Mechanisms of tumor selectivity 
1.2.1 Natural viral tropism for cancer cells and general 
mechanisms of oncolysis 
OVs have been generally categorized into DNA and RNA viruses and 
further divided into double- and single-stranded. OVs demonstrate a 
natural ability to infect cancer cells selectively and more efficiently than 
normal cells. Cancer cells have several distinct hallmarks that separate 
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them from normal cells: sustained growth signals, insensitivity to anti-
growth signals, evasion of apoptosis, increased angiogenesis, cell 
immortality and evasion/metastasis (Hanahan et al.; 2000; Hanahan et al.; 
2011). Cells infected with viruses show many of the same properties as 
transformed cells, as viruses have developed various mechanisms to 
replicate within the host evading its immune system. Infact, some viruses 
naturally exploit the aberrant signaling pathways that sustain cancer 
growth to selectively infect and replicate within cancer cells as opposed to 
normal cells. For instance, constitutively active AKT (protein-kinase B) 
pathway signaling serves as a sustained growth and survival signal in 
many diferent types of cancer (Testa et al.; 2001). Wang et coll.  
demonstrated that the natural tropism of mixoma virus in cancer cells 
exploits the endogenous AKT activity via complex formation between 
AKT and M-T5, a myxoma viral protein (Wang et al.; 2006). OVs can 
enter within cells through fusion with the plasma membrane or through 
binding to receptors in their surface. Infact, another mechanism of action 
by which viruses may selectively bind to and infect cancer cells is the 
overexpression of selected surface receptors. In squamous cell carcinoma, 
higher expression of the cell surface adhesion molecule nectin-1 was 
correlated with the increase HSV-1 infection and citotoxicity compared to 
cells that had lower nectin-1 levels (Yu et al.; 2005). Measles virus has 
been shown to use the surface receptor CD46 for cellular entry, wich is 
overexpressed in a variety of human cancers, including hepatocellular 
carcinoma, colorectal cancer, ovarian cancer and breast cancer (Dorig et 
al.; 1993; Anderson et al.; 2004). Furthermore, OVs can also take 
advantage of a deficient anti-viral defense mechanism in cancer cells. 
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When normal cells are infected by viruses, release of interferons (IFNs) 
and activation of tool-like receptors (TLRs) by recognition of viral 
elements activate several downstream pathways, leading to protein kinase 
R (PKR) activation (Kaufman et al.; 2015). Phosphorylated PKR 
subsequently blocks protein synthesis and prevents viral replication in the 
cell. Cancer cells may have abnormal IFN pathways and/or abnormal PKR 
activity, making them more susceptible to viral infection.  
An essential characteristic of an oncolytic virus is the ability to establish 
lytic cycle in malignant but not normal tissues, either by naturally 
exploiting inherent tumor weaknesses, such as RAS pathway activation 
(Strong et al.; 1998; Alain et al.; 2007) or by genetic modification. For 
example, knockdown of TK gene in HSV can lead to preferential killing of 
tumor cells, as TK-negative HSV can replicate only in dividing cells 
depending on their TK activity (Jamieson et al.; 1974; Field et al.; 1978; 
Martuza et al.; 1991). Thymidine kinase (TK), an important enzyme 
involved in viral DNA synthesis and repair (Whitley et al.; 2001) is highly 
expressed in activated cells in G1 phase in vitro (Gasparri et al.; 2009). 
OVs can establish a niche of continous viral replication within the tumor, 
to recruit uninfected cells nearby generating syncithia, to infect dividing 
and non-dividing cells, and to be stable in vivo, yet lack chromosomal 
integration and do not result in major disease (Verheije et al.; 2012). OVs, 
like reovirus (Prestwich et al.; 2008), HSV (Toda et al.; 1998; Toda et al.; 
1999), or vaccinia virus (Thorne et al.; 2008), can induce tumor–specific 
adaptive immune responses and indirectly cause malignant cell death. 
Adenovirus (Diaconu et al.; 2012), Coxsackie B3 (Miyamoto et al.; 2012) 
and measles virus (Donnelly et al.; 2013) can lead to endoplasmatic 
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reticulum stress and cause immunologic cell death, a type of cell death that 
leads to release of danger-association molecular patterns, like adenosine 
triphosphate, calreticulin and high-mobility group box-1, which attract 
immune cells (Kepp et al.; 2001).  
OVs can also selectively target tumor neo-vasculature. Vescicular 
stomatitis virus (VSV) can selectively infect endothelial cells and cause 
thrombosis in the tumor vessels (Breitbach et al.; 2011); HSV and vaccinia 
virus can also selectively damage tumor endothelium (Benencia et al.; 
2005; Breitbach CJ, et al.; 2013). OVs can be also genetically engineered 
to express anti-angiogenetic factors, like vascular endothelial growth factor 
(VEGF) inhibitors (Zhang et al.; 2005; Gholami et al., 2014). 
 
1.2.2. Mechanisms of action 
The mechanisms of action of OVs are still incompletely understood; 
however, the overall antitumor effect induced by oncolytic viral treatment 
has as major components the local cell death of both virally-infected and 
non-infected cells and induction of the systemic immune response to 
virally-induced cell destruction within the tumor. OVs mediated tumor cell 
death via direct and indirect mechanisms, working as both direct cytotoxic 
agents and therapeutic cancer vaccines. These mechanisms are connected 
by the propensity of many OVs to induce immunogenic forms of tumor 
cell death, including immunogenic apoptosis, necrosis, pyroptosis and 
autophagic cell death, wich activate host immune responses (Boozari et al.; 
2010; Myamoto et al.; 2012). Immunogenic cell death (ICD) is a type of 
cell death that leads to robust antitumor immune responses (Guo et al.; 
2015). OVs infection of cancer cells induced cell death through the above 
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cited mechanisms, which are often dependent on either the virus type, the 
cancer cell type or a combination of both (Elankumaran et al.; 2006). OV-
mediated cell death induces the release of cytokines, tumor-associated 
antigens (TAAs) and other danger signals, including damage-associated 
molecular pattern molecules (DAMPs) and pathogen–associated molecular 
pattern (PAMPs) molecules. The host immune response to these signals 
has been associated with local release of cytotoxic perforins and 
granzymes, that can kill adjacent non-virally infected tumor cells, the so 
called “immune-associated” bystander effect (Obeid et al.; 2007; 
Schietinger et al.; 2010). In addition, some OVs also target tumor 
vasculature, leading to death of uninfected tumor cells due to loss of the 
tumor blood supply (Breitbach et al.; 2007; Liu et al.; 2008). Except for 
apoptosis, the modalities of cell death listed above are highly 
immunogenic, leading to activation of both the innate and adaptive 
immune responses. ICD can induce antitumor immune response via 
dendritic cells (DC) activation. Direct oncolysis of OV-infected cancer 
cells leads to release of TAAs, that can be used to generate antigen-
specific antitumor immunity (Bartlett et al.; 2013). Antigen presenting 
cells, such as DCs, are crucial mediators of innate and adaptive immunity, 
faciliting the generation of immune responses by releasing of cytokines 
and activating naive T cells. Recruited to sites of infection and 
inflammation, DCs capture viral and tumor antigens released during 
oncolysis and present them to naive T cells, thereby initiating the 
generation of antigen specific adaptive immune reponses that mediate 
destruction of residual and recurrent tumor cells (Prestwich et al.; 2008). In 
addition to releasing OV specific PAMPs, OV mediated cell death also 
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release DAMPs, including adenosine triphospate (ATP), calreticulin, heat 
shock proteins (HSPs) and hig mobility group box 1 (HMGB1) protein 
(Obeid et al.; 2007; Zitvogel et al.; 2010; Borde et al.; 2011; Tang et al.; 
2012). The tumor microenvironment (TME) is often characterized by a 
state of immunodepression. Tumors overexpressed cytokines like 
interleukin-10 and transforming growth factor-ß (TGFß), which inhibit 
natural antitumor immune responses. Therefore, tumor derived cytokines 
and chemokines also include those promoting growth and vascularization 
like tumor necrosis factor-α (TNF-α) and vascular endothelial growth 
factor (Prestwich et al.; 2010). OV infection stimulates the release of 
cytokines (IL-1, IL-6, IL12, IL-18, IFNs AND TNF-α) and chemokines 
from infected dying cells, resident and infiltrating immune cells, altering 
the balance of pro- and anti-inflammatory factors within TME. Viral 
infection and resulting localized inflammation enhance the action of 
infiltrating immune cells and faciltate the generation of antitumor 
immunity (Guidotti et al.; 2001). The presence of TAAs, DAMPs, PAMPs 
and cytokines stimulate the antigen presenting cells (APC) maturation 
which primes T lymphocytes in the adaptive host immune response by 
cross presentation (Aymeric et al.; 2010; Bartlett et al., 2013; Guillerme et 
al.; 2013). Therefore, type 1 IFNs and DAMPs also directly stimulate 
natural killer (NK) cell response against cancer cells, so the innate immune 
system is also involved in OV mediated cell death (Kaufman et al.; 2015). 
OV mediated cell death also received a significant contribution from 
neutrophils (Di Carlo et al.; 2001; Zhang et al.; 2012). Neutrophils are the 
firts immune responders, being thus responsible for initiating an 
antimicrobal response at sites of infection (Drescher et al.; 2013).  Once 
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activated, in addition to secreting the TNF-related apoptosis inducing 
ligand (TRAIL) and TNF-α, neutrophils also generate a large quantity of 
reactive oxygen species (ROS), which disseminated cell death (necrosis, 
necroptosis), contributing to further inflammation and to the oncolytic 
effect (Drescher et al.; 2013; Dey et al.; 2016).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Immunogenic cell death (ICD). Oncolytic viruses induce ICD, wich activate 
host immune responses (https://www.frontiersin.org).  
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1.2.3 Immunological barriers to successful OVT  
The multimodal immunogenic cell death mediated by viral infection and 
oncolysis activate innate and adaptive immune responses that contribute to 
killing tumor cells; however, host immune responses to viral infection can 
be detrimental to overall efficacy of OVT (Figure 1). Numerous preclinical 
studies have demonstrated in immunocompetent compared to immune-
compromised hosts reduced viral replication, earlier clearance and 
decreased antitumor efficacy (Nemunatitis et al.; 2003; Parato et al.; 2005; 
Thorne et al.; 2006). The systemic antitumor response can result in 
clearance of OV by antibodies generated against viral PAMPs and/or 
cytotoxic T cells that recognize viral PAMPs (Kaufman et al.; 2015). NK 
cells have also been directly implicated in decreasing the efficacy of viral 
therapy via upregulation of natural citotoxicity receptors in virally-infected 
cells (Alvarez-Breckenridge et al.; 2012). 
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Figure 2. Immunologic barriers to successful oncolytic virotherapy: (1) the presence 
of neutralizing antibodies, complement proteins, and sequestration in organs such as 
the liver and spleen interfere with the oncolytic virus delivery to tumor sites (2) 
cellular antiviral responses, such as type I interferon signaling limits viral replication 
within tumor cells; (3) destruction of infected tumor cells by cells of the innate 
immune system (neutrophils, macrophages, NK cells) prematurely terminates viral 
infection; (4) tumor-induced immunosuppression (elaboration of immunosuppressive 
cytokines, accumulation of regulatory T cells, overexpression of negative checkpoint 
regulators of T cell function) inhibits the generation and effector functions of antigen-
specific antitumor immune responses. (Filley et al.; 2017).  
 
 
1.2.4 OVs and innate immunity  
Viral infection triggers the production of antiviral proteins, synthesis of 
cytokines and recruitment of immune cells to the site of infection. Viral 
replication is inhibited by type 1 IFNs that reprogram gene expression in 
infected and uninfected cells; IFNs also induce cell cycle arrest and 
apoptosis, upregulate major histocompatibility synthesis and drive the 
development and proliferation of memory T cells (Guidotti et al.; 2001). 
Among the innate immune cells, APCs, neutrophils and NK cells are the 
first responders to viral infection (Guidotti et al.; 2001). In particular 
neutrophils react to viral pathogens by secreting reactive oxigen species 
and proteases, inducing necrotic cell death and localized inflammation 
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(Khuri et al.; 2000). In a heterotopic murine model of colon cancer, 
intratumoral neutrophlis accumulation in response to OV infection resulted 
in tumor vasculature destruction and widespread tumor cell apoptosis 
(Breitbach et al.; 2007). NK cells have been shown to be key effectors of 
OV-induced antitumor immune responses (Prestwich et al.; 2009; 
Miyamoto et al.; 2012;). They target cells lacking MHC molecules or 
displaying virally induced markers of cellular stress and induce cell death 
by releasing granzyme and perforin enzymes and activating apoptosis 
(Guidotti et al.; 2001; Thorne et al.; 2006). The agonist/antagonist 
relationship of the immune system and OV is not static but evolves with 
the phase of the infection and tumor destruction. In order to exert maximal 
therapeutic effects, OVs must persist long enough and induce sufficient 
oncolysis to stimulate the generation of long lasting adaptive antitumor 
immunity. Viruses are foreign pathogens and naturally stimulate host 
immune responses mediating their clearance. Destruction of infected tumor 
cells by innate immune cells and viral antigen-specific T cells can also 
terminate OV infection before full therapeutic effects have been achieved 
(Breitbach et al.; 2007). Transient suppression of host early immune 
responses could be a potential chance to improve OV delivery to tumor 
sites, prolong viral infection and enhance the overall therapeutic efficacy 
of OVT. Inhibiting early intratumoral immune cell infiltration with low 
dose chemotherapy or TGF-β treatment has been shown to enhance viral 
replication, decrease clearance and improve antitumor effects in several 
murine models of glioma (Fulci et al.; 2006; Kurozumi et al.; 2007). 
Pretreatment with immunosoppressive chemotherapeutics like 
cyclophosphamide has been shown to improve viral delivery, promote 
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replication and enhance oncolytic effect of HSV-based OVs in murine 
models of glioma by depleting antiviral antibodies and impairing 
complement function (Fulci et al.; 2006; Ikeda et al.; 2000 a, b). 
 
1.3 OVs and clinical trials   
Several ongoing clinical trials are testing the safety and efficacy of OV 
agents alone or in combination with chemo- and/or radiotherapy. OVs 
have been generally categorized into DNA and RNA viruses and further 
divided into double- and single-stranded.  
 
1.3.1. DNA Viruses 
 
1.3.1.1. Herpesviruses  
Vectors based on herpes simplex virus (HSV)-1 are, together with the 
adenoviruses, furthest along in their development and testing for 
virotherapy. The first replication-competent vector for cancer therapy 
(malignant glioma) based on HSV-1 F strain was described in 1991 
(Martuza et al.; 1991). This vector was deleted in the TK gene but was 
shown to be oncolytic to human glioma xenografts in nude mice. Although 
TK-negative HSV vectors are attenuated in normal cells, the deletion of 
this gene eliminates the possibility to use commercial anti-herpetic drugs 
to control the infection.  
The most HSV vectors in therapy use today are deleted for the main 
neurovirulence gene γ34.5, which severely restricts their ability to replicate 
in the adult central nervous system and to form latency. These mutated 
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vectors have been the first HSV vehicles to enter clinical trials (Markert et 
al.; 2000). However, in order to avoid the generation of wild-type (WT) 
HSV, the so called second generation vectors have been deleted in several 
genes. The γ34.5 gene deletion reduced replication efficiency; therefore, 
modifications restoring the efficency have been introduced in the 
following generations. The third-generation vector G47Δ has been deleted 
for the ICP47 gene and shows increased replication efficacy and oncolysis 
in animal models compared to the parental G207 vector (Todo et al.; 
2001). To date, five replication-competent HSV-1 vectors have entered 
clinical trials: the first generation vector 1716, a recombinant based on 
HSV-1 strain 17 and deleted of  γ34.5 gene; NV1020 (formerly R7020), a 
chimeric second generation recombinant of HSV-1 and HSV-2 with 
deletions in the UL24 and UL 56 genes and in one copy of the γ34.5 gene; 
the second generation vector G207 deleted in ICP6 gene (ribonucleotide 
reductase) and both copies of the γ34.5 gene; OncoVEX (GM-CSF), a 
recombinant vector deleted in the γ34.5 gene but engineered to express 
higher levels of US11 wich compensates for the reduced replication 
efficiency; the HF10 vector, a multiple mutation recombinant HF strain of 
HSV-1 (Varghese et al.; 2002; Nakao et al.; 2002). In addition to the 
modified vectors described above, HSV variants with full replication 
efficiency and less cytotoxic than clinical isolates have been generated by 
serial passage on human cancer cells in cell culture (Taneja et al.; 2001). 
Furthermore, the oncolytic capacity of many HSV vectors has been 
augmented by various inserts. One of this strategy has been to produce 
cytokines and chemokines (e.g.IL-12 or GM-CSF) from the vectors to 
stimulate immune responses (Epstein et al.; 2005). Many vectors exist 
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derived from other members of the herpesviridae family. Notably, since 
also herpes simplex type 2 is a human pathogen, interest in this virus has 
resulted in its development into an oncolytic vector (Fu et al.; 2006). The 
vector FusOn-H2, was created by deletion of the ICP10 ribonucleotide 
reductase gene, corresponding to the ICP6 gene in HSV-1, which 
eliminates the tumorigenic potential of the vector and confers syncytia-
forming properties. Indeed, when compared to the others oncolytic vectors 
based on HSV-1, FusOn-H2 demonstrated more efficacy even after 
intravenous (i.v.) administration in a nude mouse model of human breast 
cancer. Making use of the natural tropism of Epstein–Barr virus (EBV), a 
recombinant non-oncolytic vector based on the prototype strain B95.8 was 
recently created for targeting of B-cells which are otherwise notoriously 
difficult to transduce (Hellebrand et al.; 2006). This vector, expressing 
granulocyte-macrophage colony-stimulating factor (GM-CSF), was able to 
induce maturation of DCs in vitro and to induce specific T-cell activation, 
and is thus being considered for vaccination against B-cell lymphomas. 
Furthermore, it was recently shown that replication- competent bovine 
herpesvirus 4 was oncolytic for several cancer cell lines in culture and 
destroyed human A549 lung carcinoma xenografts in nude mice (Gillet et 
al.; 2005). The apoptosis was shown to be dependent on the expression of 
viral genes. In addition to conventional HSV vectors, vehicles based on 
saimiri virus, the prototype of the c-2 subfamily of herpesviruses, represent 
a promise as a new virotherapeutic vector. These viruses can persist non-
lytically in T-cells, and when engineered to express TK, they have shown 
significant anti-tumoral efficacy in animal models of leukemia. Non-
oncolytic amplicon vectors based on the roseoloviruses human herpesvirus 
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6A and 6B and 7 are being developed for tumor vaccination (Frenkel et al.; 
2006). HHV-6 infects lymphocytes and macrophages via the CD46 
receptor and HHV-7 shows strict CD4 T-cell tropism. Finally, vectors 
based on equine herpesvirus 1 have recently been constructed, but these 
have not yet been tested for oncolytic cancer therapy. The main advantages 
of herpesvirus vectors are their capacity to carry large transgenes, safety 
issues such as neurotoxicity at high virus doses, the possible oncogenicity, 
but there is the risk of recombination with or activation of endogenous 
herpesviruses.  
 
1.3.1.2 Vaccinia viruses  
In early Phase I studies, ITu JX-594, a genetically engineered TK-
mutant/GM-CSF expressing VAC, demonstrated promising results in 
patients with melanoma (Mastrangelo et al.; 1999) and hepatocellular 
carcinoma (HCC) (Park et al.; 2008).  A study group of 10 patients with 
melanoma received ITu injections of JX-594 (Hwang et al.; 2011). In 
another Phase I trial, JX-594 was directly injected into HCC; the injection 
was well tolerated and associated with viral replication, decreased tumor 
perfusion and tumor necrosis (Heo et al.; 2011). The treatment was 
followed by therapy with sorafenib; the sequential therapy regimen was 
well tolerated and associated with decreased tumor perfusion, with tumor 
necrosis up to 100%. JX-594 has also demonstrated systemic delivery 
potential. The results of a Phase I dose-escalation trial of IV JX-594 in 
patients with metastatic tumors showed selective activity, replication and 
expression of transgene products in cancer tissue in a dose-related trend 
(Breitbach et al.; 2011). JX-594 was tested also in a Phase I dose-
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escalation trial in patients with metastatic, refractory colorectal cancer (Lee 
et al.; 2013). A Phase II study comparing intravenous and intratumoral Jx-
594 injections in patients with advanced HCC have progressed on 
sorafenib, is underway (Heo et al.; 2013).  
 
1.3.1.3 Adenoviruses 
Adenoviruses were isolated in 1953 from human adenoid tissue samples in 
culture undergoing ‘‘spontaneous’’ regression, and were dubbed 
adenoidal–pharyngeal–conjunctival viruses based on their capacity to 
induce disease symptoms in experimentally infected humans (Rowe et al.; 
1953). Since then adenoviruses have become the most widely used and 
most extensively studied viruses for oncolytic therapy. In China, oncolytic 
adenovirus mutants in combination with chemotherapy have been accepted 
as a standard treatment form for refractory nasopharyngeal cancer. The 
immediate-early genes E1 are expressed promptly upon adenovirus entry 
into a cell. In particular, two genes of this group have been the targets of 
modification in order to create tumor-specific viruses: E1A and E1B 
(E1B55K). Normally the products of these genes act in concert to force the 
host cell to enter S phase, a prerequisite for the rest of the viral replication 
process. Deletion of E1A will render the virus susceptible to the antiviral 
mechanisms of the retinoblastoma (Rb) protein, specifically by blocking 
the G1 to S transition. Deletion of E1B, on the other hand, allows p53 to 
induce apoptosis in infected cells, aborting replication and spread of the 
virus. Therefore, productive replication of adenoviral E1-deletion mutants 
can only take place in cells deficient in Rb and p53. Most gliomas fulfill 
these requirements and thus become ample targets for selective oncolysis 
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by adenoviral E1-deletion mutants (Jiang et al.; 2006).  An example of an 
E1B-negative adenovirus (dl1520) is the Onyx-015 vector, which is 
frequently used in both experimental and clinical gene therapy (Rogulski et 
al.; 2000; Kirn et al.; 2001; Nemunaitis et al.; 2001; Geoerger et al.; 2002; 
Reid, 2002; Aghi et al.; 2005;). In a Phase II study of 37 patients with head 
and neck cancer, ONYX-015 was combined with chemotherapy. It was 
approved for human use in China in 2006 (Garber et al.; 2006) but its 
clinical development in the United States and Europe has been stopped 
since 2000 due to lack of efficacy. E1A-deletion mutants, such as D24 
(dl922–947), have shown superior oncolytic efficacy compared to E1B 
mutants both in vitro and in vivo (Fueyo et al.; 2000; Heise et al.; 2000). 
To further enhance the oncolytic efficacy of E1A mutants they can be 
engineered to express functional p53, such as the commercial vector 
ADVEXINTM (Introgen Therapeutics Inc.), which enhances late stage 
replication in p53-deficient tumor cells by inducing apoptosis and 
facilitating the release of new virions (Merritt et al.; 2001; Van Beusechem 
et al.; 2002). This strategy is being implemented in several clinical trials 
(Vecil et al.; 2003).  
Therefore, several retargeting strategies have been developed. For 
example, the incorporation of tumor-targeting peptides into the fiber 
protein of adenoviruses has been shown to increase both the specificity and 
oncolytic efficacy in glioma cells (Yoshida et al.; 1998; Shinoura et 
al.;1999). Similarly, placement of an RGD-motif into the fiber knob of a 
replication competent adenoviral vector dramatically enhanced its 
oncolytic efficacy in A549 human lung carcinoma xenografts in nude mice 
(Suzuki et al.; 2001).  The currently employed adenoviruses in clinical 
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trials are all based on human adenovirus serotype 5, although they employ 
different modes of tumor selectivity. Several other adenoviral vectors have 
been investigated and developed. For example, although not specifically 
developed for human use, canine adenoviral vectors have been used in 
mouse models for cancer with promising results (Hemminki et al.; 2003). 
Further, vectors based on both porcine and bovine adenoviruses are 
available, showing efficient transduction of many human cell lines 
(Bangari et al.; 2005). The ovine adenovirus type 7 vectors OAdV623 and 
OAdV220 have been tested in animal models of cancer with good results 
(Voeks et al.; 2002; Wang et al.;2004). Finally, a recombinant vector based 
on the avian adenovirus chicken embryo lethal orphan (CELO) virus and 
expressing TK displayed (in combination with relevant prodrugs) modest 
oncolytic capacity in several human cancer cell lines in vitro and 
prolongation of animal survival in an immunocompetent mouse model for 
melanoma (Shashkova et al.; 2005). As with most non-human 
adenoviruses, CELO does not replicate productively in human cells and is 
therefore replication-deficient. It is possible to utilize these non-human 
adenoviruses in translational research and in the future, they may be 
applied in clinical settings in humans. 
 
1.3.1.4 Parvoviruses  
Parvoviruses are non-enveloped single-stranded DNA viruses. The family 
includes the helper-dependent viruses (AAV), wich require molecular 
functions supplied in trans via co-infection with herpes- or adenoviruses, 
and the autonomous parvoviruses that can replicate with the help of 
cellular factors. Only autonomous viruses are oncolytic agents, although 
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both display oncosuppressive effects. The mechanisms of action of these 
viruses are different; for example, they can inhibit the transforming 
capacity of other oncogenic viruses (Mousset et al.; 1982), and have been 
shown to suppress the proliferation of some cancer cell lines by inducing 
cell cycle arrest and terminal differentiation (Bantel-Schaal et al.; 1995). 
However, the non-structural proteins of parvoviruses can cause epigenetic 
modifications in cancer cells and revert them to a benign phenotype (Iseki 
et al.; 2005). PV B19 can induce apoptosis in erythroid cells through non-
structural proteins (NS1)-induced caspase 3 activation (Morey et al.; 1993; 
Bauder et al.; 2000). ParvOryx01 is a first in humans, Phase I/IIa, dose-
escalation study of H-1PV given locally and through systemic 
administration in patients with recurrent glioma (Geletneky et al.; 2014). 
Thus, antitumor effect by these viruses may involve both oncolysis and 
tumor suppression/reversion (Cornelis et al.; 2004). Several members of 
the dependent viruses have been used for cancer therapy (Li et al.; 2005). 
Some data reported that the tumor-trasduction efficacy of five different 
AVV strain was compared, and it was demonstrated that serotype 2 was 
the most efficient killer of solid tumor cells (Hacker et al.; 2005). 
Dupressoir et coll. (Dupressoir et al.; 1989) demonstrated the oncolytic 
capacity of the autonomous rodent parvovirus H-1 in a mouse model of 
mammary cancer. However, this study underlines an important safety 
aspect, since the virus used did not cause tissue damage and its replication 
in non-tranformed cells was considerably attenuated. Dupont et coll. 
(Dupont et al.; 2000) showed the oncolytic effect of a recombinant tiny 
virus of mice in a panel of cancer cells. Finally, parvovirus types unable to 
infect human cells can be used to target human cancer cells by capsid 
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retargeting. For example, a modified feline panleukopenia virus is a 
currently being tested as a cancer targeting tool (Maxwell et al.; 2001).  
 
1.3.2 RNA viruses 
 
1.3.2.1 Reoviruses  
Reoviruses are very common in the human respiratory and gastrointestinal 
tracts (up to 100% seropositivity in the adult population, not associated 
with any disease). These viruses are oncolytic and show high tumor-
specificity upon remote administration, while they are attenuated in 
healthy tissue. Reoviruses preferentially target cancer cells based on their 
higher rates of cell division, which differs from that of normal cells (Gong 
et al.; 2014). For example, marked inhibition of tumor growth and 
prolonged survival of immunocompetent mice were observed upon 
multiple intravenous (i.v.) injections in a model of lung-metastasizing 
mammary cancer. The oncolytic efficacy was reduced in pre-immunized 
animals, indicating that pre-existing immunity represents an obstacle, but 
combining treatment with immunosuppression agent overcame the 
restriction (Hirasawa et al.; 2003). In another study, reoviruses 
administered intracranially (i.c.) were able to eradicate breast cancer 
metastases in the central nervous system (CNS) of nude mice (Yang et al.; 
2004). The replication of reoviruses is inhibited in normal cells by the 
cellular anti-viral defense mechanisms, which is activated by recognition 
of the viral genome by the enzyme protein kinase R (PKR); the main 
advantage of these viruses is their well-established safety profile in man. 
An unmodified, non-pathogenic, type 3 Dearing reovirus strain (Reolysin) 
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has been extensively evaluated in preclinical models and clinical studies. 
This RV has a dual mechanism of action including the selective lysis of 
tumor cells and induction of an anti-tumor immunity. The selective 
permissiveness of cancer cells to reovirus replication and lysis is 
dependent from endogenous and exogenous factors. The formers are 
defective PKR signalling, RAS activation and/or mutations of RAS-
effector proteins that downregulate the IFN-induced antiviral response and 
dysfunctional or deleted tumor suppressor-genes (e.g., p53 and ATM) 
(Yoshida et al.; 1998; Glasgow et al.; 2004). Exogenous factors include 
cellular stress deriving from chemo- and/or radiotherapy and reovirus 
modulation of interferon signalling (Nakayama et al.; 2006; Stoff-Khalili 
et al.; 2006). These factors allow for viral replication, oncolysis and cancer 
cell death; the presence of infected cell and the release of viral- and tumor-
associated antigens after tumor cell death induce the innate and adaptive 
immune responses (Prestwich et al.; 2008; Hall et al.; 2012; Adair et al.; 
2013). Therapy using Reolysin has also demonstrated synergy and/or 
additive effects with standard chemotherapies (Wadler et al.; 2004; Sei et 
al.; 2009) and immunosuppressant agents (Hirasawa et al.; 2003). 
Combination therapy can overcome pre-existing immunity to RV without 
affecting metastatic tumor regression. Reolysin is one of the best-studied 
OV and several Phase I and II trials have been completed. Several patients 
have been received RV treatment, single or in combination with 
radiotherapy or chemotherapy. It was administered with paclitaxel and 
carboplatin in patients with non-small cell lung cancer (NSCLC) 
(Villalona-Calero et al.; 2016). REO 017 was a single arm Phase II study 
of Reolysin with gemcitabine in chemotherapy-naïve patients with 
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advanced pancreatic adenocarcinoma (Mahalingam et al.; 2015); biopsies 
after treatment revealed virus localization in malignant cells, caspase-3 
activation and increased programmed death ligand-1 (PD-L1) expression 
in malignant cells (Mahalingam et al.; 2015 a, b).  
  
1.3.2.2 Paramyxoviruses   
This vast group of viruses includes prototypic members such as measles 
virus, mumps virus and the Newcastle disease virus (NDV); all of wich 
have been extensively used in cancer therapy. The specificity of these 
viruses to cancer cells likely stems from the inability of tumor cells to 
respond to type I interferons and to mount an anti-viral defense 
(Krishnamurthy et al.; 2006). However, these viruses are classified as 
being lentogenic (avirulent in poultry and not capable of producing 
infectious progeny in most tissues) and mesogenic (moderately virulent in 
chickens). 
NDV is not pathogenic in humans and has been extensively studied as an 
oncolytic agent in several different human tumor cell lines and tumor 
models (Reichard et al.; 1992; Lorence et al.; 1994). In 1965 NDV was 
used as an anti-tumor agent in humans in a clinical trial led by Dr’s Cassel 
and Garrett who used the live attenuated 73-T strain to treat a patient with 
cervical carcinoma (Cassel et al.; 1965). Over the years, the 73-T strain has 
also been used in humans in the form of oncolysates to target melanoma 
(Cassel et al.; 1977; Cassel et al.; 1992). NDV binds cells via 
hemagglutinin neuraminidase (HN) protein (Park et al.; 2003). NDV has 
been used both as an oncolysate and live virus in several clinical trials.  
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PV701 and MTH68/H are live attenuated oncolytic viral strains of NDV, 
wich have the capacity to selectively replicate in lysate tumor cells and to 
stimulate immune responses (Fournier et al.; 2012). PV701 has shown to 
replicate in tumor cells, resulting in lysis of different tumor types (Lorence 
et al.; 2003; Freeman et al.; 2006). In another study, a purified poultry 
vaccine dubbed MTH-68/H based on live attenuated NDV was 
administered i.v. to a total of 14 patients with high-grade glioblastoma 
multiforme (Csatary et al.; 2004). The PV701 strain and the other 
oncolytic NDV strains MTH-68/H and 73-T are considered mesogenic; the 
73-T strain is perhaps the most potently oncolytic of the NDV strains 
studied to date, and re-emerged in experimental cancer targeting studies 
(Sinkovics et al.; 2000; Phuangsab et al.; 2001). In addition, several other 
strains, including italien and the non-oncolyticn lentogenic Ulster strain, 
have been used to target cancer cells both in vitro and in vivo with high 
specificity (Schirrmacher et al.; 2001). Based on results from the numerous 
animal experiments and clinical trials, NDV is an extremely safe oncolytic 
agent. Mumps virus (genus rubulavirus) was also among the first 
paramyxoviruses to be tested in humans. There are different strains used to 
treat several patients with different malignancies; Urabe strain was used as 
an oncolysate to treat a variety of cancers (Neagoe et al.; 1986). One of the 
characterized mumps viruses, the live attenuated vaccine strain S79, shows 
promise as an oncolytic veichle based on its selective infection of cancer 
cells in vitro and significant tumor inhibition in nude mice (Yan et al.; 
2005). Another rubulavirus, simian virus 5, has been engineered for cancer 
targeting (Yan et al.; 2005).  
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MV enters within cells through interaction of its H protein cellular CD46 
(membrane cofactor protein) and signalling lymphocyte-activating 
molecule (SLAM) (Tatsuo et al.; 2000; Dorig et al.; 1993). The wild type 
MV enters within cells more effectively through SLAM; however, the MV 
vaccine strains enter more effectively via the CD46 receptors (Yanagi et 
al.; 2003). MV vaccine affects only cells with high density of CD46, that 
overexpressed on tumor cells (Fishelson et al.; 2003) and does not affect 
normal cells (Anderson et al.; 2004). MV kills tumor cells by inducing cell 
to cell fusion through F protein, formation of syncithia and subsequent 
apoptotic cell death (Anderson et al.; 2004; Galanis et al.; 2001). MVs 
have been used in several preclinical studies in animal models, including 
both solid tumors and hematologic malignancies; treated animal tumors 
demonstrate cytopathic effect with syncithia formation followed by 
apoptotic cell death of MV-infected tumor cells (Zhang et al.; 2012). Peng 
et coll. (Peng et al.; 2002) demonstrated the feasibility of using a 
recombinant measles vector to preferentially infect and destroy humal 
ephitelial ovarian cancer cells in vivo via CD46. Moreover, a recombinant 
vector based on the Edmonston virus and engineered to express 
carcinoembryonic antigen caused marked regression of U87 glioma 
xenografts in nude mice (Phoung et al.; 2003); this vector entered a Phase I 
clinical trial to treat glioblastoma multiforme.  
 
1.3.2.3 Orthomyxoviruses  
Influenza viruses were used for experimental cancer therapy already in the 
1950s (Wagner et al.; 1954) and later as oncolysates in clinical trials 
(Freedman et al.; 1988). Vaccination against influenza showed to provide 
   Oncolytic virotherapy  
 
 47 
protection against certain types of cancer later in life (Kolmel et al.; 2005). 
The NS1 protein of influenza virus inhibits the activity ok PKR in target 
cells, which in turn permits viral replication. PKR is also inhibited by Ras 
in many tumor cell types, which thereby constitute preferential targets for 
infection by NS1-deleted influenza virus. Recently, Bergmann et coll. 
(Bergmann et al.; 2001) reported the utilization of a recombinant NS1 
deletion mutant of influenza virus A strain PR8 that efficiently lysed Ras-
expressing cells, both in vitro and in a subcutaneous tumor model in sever 
combined immundeficient mouse (SCID); as expected, normal cells were 
shown to be resistant, constituting an important safety aspect.  
1.3.2.4 Coronaviruses  
Coronaviruses are common respiratory pathogens of mammals and birds. 
Although human coronaviruses await conversion into cancer targeting 
vectors, non-human coronaviruses, including feline coronavirus and 
murine hepatitis coronavirus A59, display significant oncolytic activity in 
human cancer cells in vitro (Wurdinger et al.; 2005; Verheije et al.; 2006). 
Viral tropism is determined only by the expression of the proper viral 
receptors on the cell surface; once inside the cells non-human 
coronaviruses are capable to initiate a productive replication.  
 
1.3.2.5 Picornaviruses 
Several members of these RNA viruses are being developed into tools for 
virotherapy. Poliovirus infects a wide type of human cancer cell lines and 
primary explants (Ansard et al.; 2001). By attenuation of a neurovirulent 
poliovirus strain, Gromeier et coll. (Gromeier et al.; 2000) obtained a 
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highly efficacious recombinant virus, PV1 (PVS)-RIPO, which displayed 
significant tumor tropism and oncolytic potential in subcutaneous and i.c. 
human astrocytoma xenografts in nude mice. In another study, this virus 
caused complete tumor regression in a small number of athymic rats 
harboring i.c. human glioma xenografts upon intrathecal administration. In 
addition to the recombinant vectors, a live attenuated strain of poliovirus 1 
showed promise as an oncolytic agent (Toyoda et al.; 2004). The RIPO 
vector has entered a phase I clinical trial to treat malignant glioma. 
Coxsackievirus was recognized as an anti-neoplastic agent in the 1950s 
and was tested for oncolytic efficacy in animal models (Suskind et 
al.;1957). To date, oncolytic vectors based on coxsackievirus A21 are 
available (Shafren et al.; 2004; Au et al.; 2005), and phase I studies in 
targeting melanoma with this virus have been completed (results not yet 
published) (Parato KA, et al.; 2005). Another oncolytic picornavirus tested 
in the 1950s, bovine enterovirus, has gained renewed attention as a 
potential oncolytic agent (Smyth et al.; 2002; Taylor et al.; 1971). This 
virus shows oncolytic potential towards a variety of human cancer cell 
types, including some of lymphoid origin. Moreover, echovirus type 1 
recently showed to dispaly a strong tropism for human ovarian cancer cells 
(Shafren et al.; 2005). Finally, live attenuated Seneca Valley virus SVV- 
001 (genus unassigned) entered phase I studies to treat carcinomas of 
neuroendocrine origin.  
 
1.3.2.6 Retroviruses  
Several members of this virus family were extensively used in different 
gene therapy applications. The most frequently used retrovirus to target 
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cancer is the Moloney murine leukemia virus (MoMLV). Due to the lack 
of active nuclear transport of the viral genome, all gammaretroviruses, 
including MoMLV, are unable to transduce nondividing cells, which can 
be considered an important safety aspect. Complete transduction of human 
U87 glioma xenografts in nude mice was reported following a single i.c. 
administration of a replication- competent MoMLV vector (Tai et al.; 
2005). Retroviruses have been used in clinical trials to treat cancer, but 
data from these studies suggest that the dissemination of the vectors in 
solid tumors needs to be improved to reach clinical efficacy (Ram et al.; 
1997; Colombo et al.; 2005). 
Some vectors based on lentiviruses were also used to target cancer in pre-
clinical experiments. For example, using equal amounts of infectious virus, 
VSV-G pseudotyped lentiviral vectors were shown to transduce a wide 
variety of tumor cells almost 10 times as efficiently as vectors based on 
adenovirus serotype 5 (Pellinen et al.; 2004). Like their retroviral 
counterparts, lentiviruses are not oncolytic. However, they have the 
capacity to transduce both dividing and non-dividing cells, which may be 
advantageous under certain circumstances. In contrast to both 
gammaretroviruses and lentiviruses, the spumavirus foamy virus shows 
intrinsic oncolytic capacity. Some data reported that replication-competent 
vectors based on the prototype strain of this virus were able to control 
subcutaneous U87 tumors in nude mice for up to 25 weeks (Heinkelein et 
al.; 2005).  
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1.4 Combination therapies  
 OV infection generates an antitumor immune response, that represents an 
indirect mechanism of malignant cell death for both infected- and non-
infected cells (Zamarine et al.; 2014). The immune response can represent 
an obstacle to the success of OV therapy; the tumor-infiltrating 
lymphocytes can suppress viral replication and finally eradicate the virus. 
Furthermore, pre-existing antibodies can also bind administered OV and 
clear it from the circulation, minimizing viral penetration. Combination 
strategies of OV with chemotherapeutic agents can potentially overcome 
those obstacles. Chemotherapy and/or radioteraphy represent the standard 
of care for many malignancies, but clinical data show that combining OVs 
with the traditional sistemic therapies can increase the response respect to 
either therapy alone. Preclinical and clinical studies have demonstrated 
significantly enhanced antitumor immune and clinical responses in patients 
receiving combination therapies (Khuri et al.; 2000; Galanis et al.; 2005; 
Karapangiotou et al.; 2012). Chemotherapy complements virotherapy 
through a variety of known and unknown mechanism, including the direct 
killing of tumor cells, enhancement of tumor cell immunogenicity and 
suppression of antiviral immune responses (Choi et al.; 2016). The first 
human clinical trial evaluated was ONYX-015 (d11520); it was a 
genetically modified adenovirus in combination with cisplatin and 5-
fluouracil in 37 patients with recurrent squamous cell head and neck 
cancer. This clinical trial showed 65% response rate in patients receiving 
the treatment, compared to just 14% response rate for virus alone (Khuri et 
al.; 2000). The mechanism of this synergistic effect between OVs and 
chemotherapy is not completely understood; some chemotherapy agents 
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may upregulate cell surface receptors that viruses use to enter and infect 
tumor cells. For example, MAP/ERK kinase (MEK) inhibitors have been 
shown to upregulate chimeric antigen receptor (CAR) expression, which 
enables enhanced adenovirus entry (Zurakowski et al.; 2007). However, 
chemotherapy agents can also enhance OV function by affecting the 
immune response to infection (Nguyen et al.; 2014). Paclitaxel upregulates 
MHC class 1 molecules expression, leading to enhanced antigen 
presentation and immune system cross-priming (Kaneno et al.; 2011). 
Cyclophosphamide showed in preclinical animal models to improve 
reovirus access to the tumor and preserve neutralizing antibody levels 
sufficient for prevention of severe toxicity (Qiao et al.; 2008). Doxorubicin 
downregulates programmed death-ligand 1 (PD-L1), which plays a role in 
immune suppression (Ghebeh et al.; 2010). OV combination therapy with 
radiation also showed to improve antitumor response in preclinical models 
by enhancing apoptosis in the combination therapy (Rogulski et al.; 2000; 
Dai et al.; 2014). Gemcitabine appears to impact negatively late phases of 
reovirus replication; however, the next effect is synergistic as it accelerates 
antitumor immunity generation most likely by decreasing 
immunosuppressive cells within the tumor microenvironment (Gujiar et 
al.; 2008). In a Phase II study of Reolysin in combination with 
gemcitabine, combination treatment did not prevent viral entry in 
malignant cells and subsequent apoptosis (Mahalingam et al.; 2015). 
Antibody response to Reolysin also appears to be attenuated with this 
combination strategy (Lolkema et al.; 2011). Intratumoral HSV-1 (G207) 
in combination with radiotherapy was used successfully in clinical trials 
for patients with recurrent glioblastoma multiforme (GBM), with six out of 
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nine patients demonstrating stable disease or partial response (Markert et 
al.; 2014). Some OVs are being engineered with therapeutic genes that 
enhance local radioactive particle delivery, in particular radioactive iodine. 
Both Vaccinia virus (VAC) and Measles virus (MV) have OV strains 
developed carrying the human sodium iodide symporter (hNIS), which 
allows entry of radioactive iodine into virus-infected cells to produce 
further tumor destruction through local radiation exposure (Dingli et al.; 
2004; Gholami et al.; 2011).  
The most promising combination therapy with OVs is with T cell 
checkpoint inhibitors. Recent discoveries in cancer immunotherapies 
showed that induction of T cell response alone is not sufficient for 
sustained antitumor effect; they point out that suppression of T cell 
inhibitory mechanism by blockade of T cell checkpoint factors, such as 
cytotoxic T lymphocyte antigen 4 (CTLA-4) and programed death 1 (PD-
1), can be useful in light of the immunosuppressive nature of advanced 
tumors (Dias et al.; 2012). There are preclinical data for synergy between 
OVs and immune checkpoint inhibition. In melanoma xenografts, the 
combination of Reolysin and anti- PD1 antibody significantly prolonged 
mice survival compared to either agent alone (Rajani et al.; 2016). There 
was evidence of enhanced antitumor cytotoxic T cell and natural killer 
(NK) cell activity with the combination therapy. Suppression of antitumor 
immunity by regulatory T cells (Treg) in Reolysin alone treated mice was 
ameliorated by anti-PD1 therapy. In an immunotherapy-resistant lung 
adenocarcinoma animal model, treatment with oncolytic adenovirus plus 
anti-PD-1 antibody, significantly increased antitumor immune responses to 
multiple neoantigens and decreased tumor growth, suggesting reversal of 
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anti-PD-1 resistance with oncolytic virotherapy (Woller et al.; 2015). 
Recent clinical trials are investigating the efficacy of OV combinations 
with ipilimumab, a monoclonal antibody against CTLA-4, and with 
pembrolizumab, a monoclonal antibody against PD-1. 
NDV combined with immune checkpoint inhibition in immunogenic and 
non-immunogenic tumor animal models led to increased antitumor 
immunity and efficacy compared to either agent alone (Zamarin et al.; 
2014). Synergy of oncolytic VSV with anti-PD1 antibody therapy was also 
demonstrated in glioma models (Cockle et al.; 2016). Oncolytic measles 
virus and adenovirus vectors have been engineered to express monoclonal 
antibodies against CTLA-4 and PD-1 with promising results; they showed 
to have improved antitumor activity compared to control virus (Dias et al.; 
2012; Engeland et al.; 2014).  
Small molecule inhibitors can potentially improve OV penetration and 
activity. Combination strategies of OV with agents targeting the 
VEGF/VEGFR pathway are based on the potential selective targeting of 
the tumor neovasculature. VEGFR TKIs can also have off-target effects on 
antiviral defense mechanisms (Jha et al.; 2011; Jha et al.; 2013). Reolysin 
showed synergy with VEGFR TKIs in vitro and in vivo in NSCLC models, 
with decrease in tumor growth and increase in antitumor immunity (Liu et 
al.; 2015).  
 
1.5 T-Vec: the first FDA-approved OV 
Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus 
type 1 (HSV-1) that was recently approved for the treatment of inoperable 
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malignant melanoma. Administered intratumorally into one or more 
accessible (usually cutaneous) lesions every 2 weeks for up to 18 months, 
the virus produced durable systemic responses in 16% of treated patients 
(Andtbacka et al.; 2015) and has since shown extraordinarily promising 
activity in the same disease indication when combined with ipilumumab or 
pembrolizumab checkpoint antibody therapy (Long et al.; 2016; Puzanov 
et al.; 2016). Efforts are now underway to explore the potential of T-VEC 
therapy across a spectrum of different cancers. 
T-VEC (or JS1/ICP34.5_/ICP47_/GM-CSF (granulocyte macrophage 
colony-stimulating factor), the virus that was to become known as T-VEC) 
was originally described in 2003 (Liu et al.; 2003). The thinking behind the 
design of this virus was that its lab-adapted, g-34.5-deleted predecessors 
had been over-attenuated. Thus, T-VEC was derived from a fresh 
pathogenic virus isolate obtained from the cold sore of a lab worker. 
Although it was initially attenuated by disrupting both copies of the g-34.5 
gene, the attenuation was partially reversed by engineering US11, whose 
product also blocks the shutoff of host cell protein synthesis, to be 
expressed at an earlier stage in the virus infection cycle. In addition to 
these de-attenuating modifications, the virus was engineered to more 
effectively boost the antitumor immune response, by achieving with the 
deletion of the ICP47 gene, whose product suppresses antigen presentation 
by the infected cell, and by inserting two copies of the GM-CSF gene into 
the virus to activate and promote the differentiation of locally resident 
antigen-presenting cells (APCs) in the infected tumor. T-VEC was rapidly 
advanced to the clinic and shown to be active in malignant melanoma, 
shrinking injected tumors and sometimes leading to the regression of 
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distant metastatic lesions (Kaufman et al.; 2010). The phase 3 T-VEC 
registration trial was launched in May 2009, 2 years before FDA approvals 
were granted for the anti-CTLA4 antibody ipilumumab and the B-raf 
inhibitor vemurafenib. Thus, the control randomization arm was 
subcutaneous GM-CSF, which has very little antimelanoma activity. 
Between May 2009 and July 2011, 436 patients with unresectable (stage 
III or IV) melanoma were randomly assigned to intralesional T-VEC or 
subcutaneous GM-CSF administered every 2 weeks. The durable response 
rate (responses lasting at least 6 months) was 16.3% in the T-VEC arm and 
2.1% in the GM-CSF arm, and T-VEC was associated with a longer 
overall survival of 23.3 months versus 18.9 months with GM-CSF.5 Based 
on these positive findings, a biologics license application was filed, and 
U.S. marketing approval was granted in October 2015, with European and 
Australian approvals granted shortly thereafter.
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2. Herpesviridae family 
Herpesviruses are a large family of dsDNA viruses whose virions are 
encased within a lipid bilayer envelope. They have a broad host range, 
infecting almost all vertebrates and some invertebrates (bivalves). The 
family includes about 200 viruses isolated by different hosts, such as 
molluscs, fish, amphibians, reptiles, birds and mammals (Roizman & 
Knipe; 2001). The name Herpesvirus, from the Greek erpein, means 
"hiding" and refers to the the ability of these viruses to induce latent 
infections that, after the depletion of clinical phase following primary 
infection, reactivated occasionally, as a result of different stimuli like a 
decrease in the immune response cell-mediated. Latency is a strategy 
implemented by the herpesvirus with the purpose of surviving in nature; 
also in the presence of an effective immune response, the virus has the 
capacity to persist within the cells in the form of episomes or extra 
chromosomal plasmids and it is able to reactivate in particular conditions 
like immunosuppression, fever and/or stress.  
The family is divided into three subfamilies: alphaherpesviruses, 
betaherpesviruses and gammaherpesviruses. 
-Alphaherpesvirinae, includes viruses characterized from large host 
spectrum, rapid replicative cycle, rapid dissemination in cell cultures with 
formation of syncythia and citoplasmic inclusions, remarkable necrotizing 
activity and finally capacity to establish latent infections in sensory 
ganglia. This subfamily includes the Simplexvirus genus and the 
Varicellovirus genus, which carpine herpesvirus type 1 (CpHV-1) belongs.  
-Betaherpesvirinae, which belong Cytomegalovirus, Muromegalovirus e 
Roseolovirus genus. They induce latent infections in endothelial, epithelial 
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and lymphoid cells; they are characterized from close host spectrum, slow 
replicative cycle and in vitro they grow only on fibroblastoid cells, with 
the formation of cytoplasmic inclusions and giant cells (cytomegaly). 
-Gammaherpesvirinae, wich includes Lymphocryptovirus e Rhadinovirus. 
They have guest host spectrum limited to the family or order of belonging 
to the natural host; they replicate in lymphoblastoid cells and, as they have 
specific tropism to T and B lymphocytes, they induced latent infection in 
the lymphoid tissues. Herpesviruses are among the largest and most 
complex kown animal viruses. Mature virion has a size ranging from 150 
to 200 nm. In viral particle, the viral genome is enclosed from the 
nucleocapside and associated to several nucleoproteins to form the 
nucleoid. The protein capside consists of cable capsomeres that determine 
an icosaedric structure of the diameter of about 100 nm; there is a layer of 
amorphous protein material named “tegument” outside the nucleocapside. 
Finally, in the portion more external, there is the envelope consisting of 
lipids, polyamides and various glycoproteins such as gH, gC, gE, gG, gI, 
gB and gD, which act as a site to adsorb the virus to the cells. The 
Herpesvirus genome consists of double linear DNA filament of about 150 
Kbp, capable of coding for necessary proteins to viral replication. 
Replication of DNA occurs in the nucleus, where the genome becomes 
circular (Garber et al., 1993; McVoy & Adler; 1994) and there is the 
formation of concatenamers (Roizman & Knipe; 2001), cut into specific 
sites to form molecules homogeneous (Deiss & Frenkell; 1986). For the 
presence of inverted and repeated sequences in the genome, these viruses 
are classified into six classes, named with the alphabet letters ranging from 
A to F. In particular, class D includes Caprine Herpesvirus 1, Varicella-
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Zoster Virus, Bovine Herpesvirus 1 and Equine Herpesvirus 1. The class D 
genome consists of covalently combined sequences, called L (long) and S 
(short), each of which consists of unique sequences (UL and US, 
respectively). The latter is lined by inverted repeats defined IR (internal 
repeat) and TR (terminal repeat). The two UL and US components can 
change orientation and form four populations of DNA molecules that differ 
only in the order of these sequences (isomers). The mechanism of action of 
replicative cycle has been studied in the Herpes Simplex Virus (HSV), 
under the subfamily Alphaherpesvirinae (White & Fenner; 1994). The 
infection begins with the adsorption of the virus to the host cell by the 
recognition of eparan sulfate, present in proteoglycans, by the viral 
glycoprotein C (gC). Proteins of the tegument release into the cytoplasm 
while the nucleocapside are transported along the cytoskeleton to the 
nuclear pores through which the DNA is released to reach the nucleus 
where it circulates. The expression of viral genes is finely regulated by a 
mechanism a waterfall; it is necessary the presence of three classes of 
mRNAs, synthesized by the cellular RNA polymerase II. Two tegument 
proteins, respectively VHS (Virion Host Shutoff) and  -TIF (a-gene Trans 
Inducer Factor), play an important role in the early stages of viral 
replication. The first is responsible for the cytoplasm disruption of 
polyribosomes resulting in blocking of cellular protein synthesis; the 
second activates the transcription of Immediate Early gene (IE) in -
mRNA. After the translation, five of the six proteins are transferred in the 
nucleus to regulate the expression of Early (E) or ß. The sixth protein 
blocks the presentation of antigenic peptides on the cell surface to escape 
from the response immune. Proteins ß are enzymes necessary to increase 
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the synthesis of nucleotides (thymidine kinase and ribonucleotide 
reductase) and also for the replication of the viral genome (DNA 
polymerase, primacy-helicase, topoisomerase). These events stimulate the 
expression of genes Late (L) or γ and thus the synthesis of L proteins, 
structural components of virion. Some are assembled to form the capside 
and tegument while others form an area on the nuclear membrane from 
which the capside will acquire the envelope. Mature virions are released 
for exocytosis. 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Graphic representation of herpetic virion. Mature virion has a size ranging 
from 150 to 200 nm; the protein capside of cable capsomeres that determine an 
icosaedric structure; there is an amorphous protein material layer named “tegument” 
outside the nucleocapside. (www.glycopedia.eu). 
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2.1 Bovine Herpesvirus 1 (BHV-1) 
Bovine herpesvirus 1 (BoHV-1) is an Alphaherpesvirus, known to cause 
several diseases worldwide in cattle, including rhinotracheitis, vaginitis, 
balanoposthitis, abortion, conjunctivitis, and enteritis. It is spread 
horizontally through sexual contact, artificial insemination, and aerosol 
transmission and it may also be transmitted vertically across the placenta. 
BoHV-1 can cause both clinical and subclinical infections, depending on 
the virulence of the strain. Like other herpesviruses, BoHV-1 causes a 
lifelong latent infection and sporadic viral shedding. The sciatic nerve and 
trigeminal nerve are the sites of latency. BoHV-1 enters the animal through 
the mucous membrane in the respiratory tract or genital tracts. BoHV-1 has 
many mechanisms to evade the host immune systems involved in both 
innate immunity and adaptive immunity. The virus degrades interferon 
regulatory factor 3 (IRF3), effectively halting transcription of interferon 
type 1 (Muylkens et al.; 2007). BoHV-1 is also able to evade adaptive 
immune cells by inducing apoptosis in CD4+ cells, which assist in 
activating T cells when antigens are present (Muylkens et al.; 2007). This 
downregulates the number of immune cells that recognize the virus, 
allowing the virus to evade detection and elimination. After primary 
infection of BoHV-1, the latent infection is quite often found in the 
trigeminal ganglion of the cow, although on occasion infection can enter 
the central nervous system (Smits et al.; 2000). These latent infections can 
possibly reactivate, with or without clinical symptoms, under conditions of 
stress or by experimental methods (Smits et al.; 2000). Infected animals 
will be continuous shedders throughout their lifetime when the virus 
reactivates; therefore, successfully propagating the disease. Aside from 
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cattle, studies experimentally infecting animals showed that goats and 
buffalo can act as reservoirs for BoHV-1, as well as red deer, sheep, swine, 
and reindeer (Muylkens et al.; 2007). Shedding begins from the nasal 
mucosa as soon as infection occurs, and the virus has replicated in the 
upper respiratory tract. During replication in the respiratory tract ephitelial 
cells will undergo apoptosis (Nandi et al.; 2009). The necrosis will result in 
an entry site for secondary infections that may result in shipping fever. 
Clinical signs are represented from rinotracheitis, fever, serous to 
mucopurulent nasal discharge, coughing, sneezing, difficulty breathing, 
conjunctivitis and loss of appetite. Ulcers are common in the mouth and 
nose. Clinical symptoms include infectious pustular vulvovaginitis in cows 
and infectious balanoposthitis in bulls, fever, depression, loss of appetite, 
painful urination, a swollen vulva with pustules, ulcers, vesicles and 
erosions in cows, and pain on sexual contact in bulls. IBR can also cause 
abortion. Clinical signs and history are normally enough to make a 
preliminary diagnosis. To definitively diagnose the infection the virus 
should be identified in the tissues by virus isolation or PCR, or in bulk 
milk samples by ELISA. Vaccination is widely used both to protect cattle 
clinically in the case of infection and significantly reduce the shedding of 
the virus. Vaccination provides herd immunity, which lowers the 
likelihood of an animal coming into contact with an infected animal. Both 
inactivated and live attenuated vaccines are available. Immunity usually 
lasts approximately six months to one year. Marker vaccines are also 
available and recommended. Marker vaccines, also known as DIVA 
(differentiation of infected from vaccinated animals), have become popular 
to discriminate vaccinated animals from infected animals. A marker 
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vaccine uses either deletion mutants or a virion subunit, such as 
glycoprotein E (Bosch et al.; 1997).  
 
2.1.1 BHV-1 Oncotropism 
One of the main features of BHV-1 is the narrow spectrum of host 
compared to other herpesviruses, including HSV-1. Thus, BHV-1 is not 
capable of infecting human cells (Murata et al.; 1999), as confirmed by the 
absence of publications related to BHV-1 production or human 
seroconversion (Hammon et al.; 1963). This suggests a blockage of BHV-1 
infection in human cells. Similarly, mice infected with wild type strains of 
BHV-1 show no clinical symptoms, while missing IFN-I and IFN-II 
receptors for RAG-2 gene deletion die a few days after infection (Abril et 
al.; 2004). As a result, IFN influences the host spectrum of the virus. From 
a study dating back to 1960, however, it emerges that BHV-1, determines a 
cytopathic effect in vitro on several transformed human cell lines, 
including HeLa, KB, HEp-2 lines and Had-1 (Hammon et al.; 1963). From 
a study to assess the susceptibility of different human tumor cell lines to 
BHV-1, it emerges that 72% of the cells are permissive to BHV-1 
infection, resulting in a reduction in cell viability. Surprisingly, the 
reduction in viability occurred at a low multiplicity of infection (MOI) and 
was also detected in semi-permissive and non-permissive cellular cell lines 
(Cuddington et al.; 2014).  
Rodrigues et coll. have demonstrated the ability of BHV-1 to replicate, to 
cause cytopathic effects and to compromise cell viability in normal, 
immortalized, and transformed cells of different histological origin 
(Rodrigues et al.; 2010). This capacity is strongly attenuated in normal 
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cells. However, it was demonstrated that BHV-1 infection of human cells 
fails to elicit IFN production at the mRNA or protein level and the ability 
of BHV-1 to kill immortalized cells does not correlate with defects in IFN 
pathways. Furthermore, although some cross reactivity between BHV-1 
and HSV-1 exists, the majority of human antibody or serum tested samples 
failed to neutralize BHV-1 despite possessing HSV-1 neutralizing 
capacity. Thus, BHV-1 represent a novel candidate oncolytic virus with a 
distinct mechanism of tumor targeting.  
 
2.2. Bovine Herpesvirus type 4 (BHV-4)  
Bovine herpesvirus type 4 is a Gammaherspevirus, genus Rhadinovirus. 
Infection is normally sub-clinical but can cause reproductive disease in 
cattle such as endometritis, vulvovaginitis and also mastitis. Transmission 
is both vertical and horizontal. It can also be indirectly spread by fomites. 
Distribution is worldwide and the virus infects a range of ruminants, 
including bison, buffalo, sheep and goats. The disease may also be referred 
to as passenger virus and moyar virus. BHV-4 infection is often 
subclinical, with no observable clinical signs. However, the virus may 
cause abortion and retained foetal membranes, and if an infected fetus is 
born alive it may be weak. It can also cause mastitis in dairy cattle. It may 
be isolated from conjunctivitis and respiratory apparatus.  
 
2.2.1 BHV-4 Oncotropism 
BHV-4 is able to replicate in a broad range of host species both in vivo and 
in vitro (Egyed; 2000); it replicates and causes CPE in a large number of 
immortalized cell lines and primary cultures, but also in some cancer cell 
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lines (D’Onofrio et al.; 2002; Gillet et al.; 2004; Gillet et al.; 2005). Gillet 
et coll. have demonstrated that in vitro BoHV-4 infection induced 
apoptosis in A549 and OVCAR cell lines in a time- and dose-dependent 
manner. Furthermore, apoptosis was induced by the expression of an 
immediate-early or an early BoHV-4 gene, but did not require viral 
replication; in vivo experiments done with nude mice showed that BoHV-4 
intratumoral injections reduced drastically the growth of preestablished 
A549 xenografts (Gillet et al.; 2005). Furthemore, Redaelli et al. have 
demonstrated that BHV-4 can infect mouse, rat and human glioma cell 
lines, primary cultures obtained from human glioblastoma in vitro and the 
ability of the virus to selectively infect gliomas induced in the rat brain in 
vivo (Redaelli et al.; 2010). These results suggest that BoHV-4 may have 
potential as a viro-oncoapoptotic agent for the oncolytic virotherapy and 
could be used to design new cancer therapeutic strategies. 
 
2.3 Caprine Herpesvirus type 1 (CpHV-1) 
CpHV-1 is an Alphaherpesvirus correlated with BoHV-1 which was 
isolated by 7-day-old kids with severe enteritis for the first time in 1974 in 
California (Saito et al.; 1974). A few years later, in 1979, it was found in a 
Swiss breeding farm (Mettler et al.;1979). The virus was identified not 
only in several European nations, including Italy (Roperto et al.; 2000), 
Greece (Koptopoulos et al.; 1988), Spain (Keuser et al.; 2004), Germany 
(Muluneh et al.; 1990) and Switzerland (Plebani et al.; 1983), but also in 
Australia (Grewal et al.; 1986; Piper et al.; 2008), Canada (Chenier et al.; 
2004), California (Uzal et al.; 2004), New Zealand (Horner et al.; 1982). 
The prevalence of the disease is variable: in some countries, such as 
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Greece or in southern Italy, where goats represent an important economic 
source, is elevated (Koptopoulos et al.; 1988; Tempesta et al.; 1994; 
Guercio et al.; 1998). While, so far, no related data were reported on the 
identification of infection in Belgium and Great Britain. The pathogenesis 
of CpHV-1 infection in goats and BoHV-1 in the cattle is very similar; it is 
localized to respiratory or genital tract and subsequently the viremia 
associated to the mononuclear cells occurs, which results in systemic 
infection and abortion. The primary source of infection is represented by 
animals with acute infection or latent ones that can eliminate the virus 
through nasal, ocular and genital drain. The genital apparatus represents 
the entrance site of the virus and it is responsible for the persistence of 
infection in breeding (Tempesta et al.; 2000). CpHV-1 is responsible for 
two different forms of disease in the goat; it dipends from the age of 
animals. In adults, the infection may remain unapparent or appears with 
symptoms wich affect genital and respiratory apparatus, such as 
vulvovaginitis/ulcerative balanopostitis, dyspnoea, proliferative lesions on 
lips and hard palate (Horner et al.; 1982; Rosadio et al.; 1984; Williams et 
al.; 1997; Tempesta et al.; 1998). Abortion can also be manifested during 
the second half of the pregnancy, reproducible by experimental infection, 
through intranasal and intravenous inoculation of the virus (Tempesta et 
al.; 2004; Uzal et al.; 2004). In the kids of two weeks of life, however, 
CpHV-1 induces systemic disease characterized by high morbidity and 
mortality, rapid beginning and progressive slimming which often leads to 
death (Saito et al.; 1974; Mettler et al.; 1979; Van der Lugt & Randles; 
1993; Buonavoglia et al.; 1996). From the anatomy-pathological point of 
view, CpHV-1 causes erosive, ulcerative and necrotic lesions on the 
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gastro-intestinal mucosa, especially in the large intestine; however, it is 
also responsible for pulmonary edema, hemorrhagic lesions on the bladder 
mucosa and hepatic necrosis. The istopathological examination underlines 
the loss of epithelial cells of the intestinal mucosa, while the lamina 
propria is infiltrated by mononuclear cells, especially macrophages 
containing intracellular eosinophilic inclusions; however, there is necrosis 
of lymphoid tissues (Roperto et al.; 2000). Like other Alphaherpesviruses, 
CpHV-1 is capable to interfere with the host immune responses (Hutchings 
et al.; 1990; Tempesta et al.; 1999; Hinkley et al.; 2000; Barcy & Corey; 
2001; Pagnini et al.; 2005), and to establish latent infections susceptible to 
reactivation (Engels et al.; 1983). After infection and viral replication in 
the genital and respiratory apparatus, CpHV-1 spreads both in the 
extracellular spaces and from cell to cell. Through these mechanisms, it 
has the capacity to penetrate into the axons of the nervous cells and thus to 
reach the bodies of sensory neurons, in the regional ganglia. Generally, 
reactivation of the infection is observed during the reproductive season, 
while in experimental conditions it is difficult to obtain it (Buonavoglia et 
al.; 1996; Tempesta et al.; 2002); after the reactivation, the pathogenesis of 
the infection is similar to the primary infection, or rather the animals 
infected through nasal way eliminate the virus by both ways (nasal and 
vaginal), while vaginal infected ones eliminate the virus only by this way 
(Tempesta et al.; 2000). Viral excretion, after reactivation, is associated 
with relatively low antibody titres (Tempesta et al.; 1998) and it occurs 
through nasal, genital, rectal and ocular secretions; this evidence suggests 
the presence of several potential latency sites, such as sacral ganglia, 
where the presence of viral DNA was detected by PCR (Tempesta et al.; 
   Herpesviridae family  
 
 68 
1999; Tempesta et al.; 2002). The diagnosis of suspected infection can be 
done with clinical signs, wich are characteristic but not pathognomonic; 
the confirmed diagnosis can be done through direct or indirect methods. 
The direct method is the virus isolation on cell culture from nasal and 
genital secretions; it is evaluated the citophatic effect virus induced on a 
permissive cell line (Berrios et al.; 1975; Engels et al.; 1983). The indirect 
methods include serological techniques like serum neutralization and 
ELISA tests (Plebani et al.; 1983), although there could be cross-reactions 
caused by Alphaherpesvirus correlated (Nixon et al.; 1988; Lyaku et al.; 
1992; Lyaku et al.; 1996). In order to avoid the cross-reactions, it is 
possible to resort to the molecular biology which allows the amplification, 
in positive samples, of a 414 bp fragment (Tempesta et al.; 1998), and real-
time PCR, a quantitative analysis for the detection and quantification of 
viral DNA in goat (Elia et al.; 2008). Furthermore, another technique 
which allows the identification of isolated viruses and the discrimination 
from related microorganisms is Restriction Endonuclease Analysis (REA) 
(Rimstad et al.; 1992; Williams et al.; 1997; Pratelli et al.; 2000). At the 
current state of knowledge, prophylaxis is exclusively healthcare. There 
are no immunizing prescriptions, although several experimental studies 
demonstrate the possibility of protecting goats with inactivated vaccines 
(Tempesta et al.; 2001) and live attenuated etherologists (Thiry et al.; 
2006). 
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3. Mechanisms of cell death 
3.1 Apoptosis (PCD I) 
Apoptosis is a basic biological phenomenon with wide-ranging 
implications in tissue kinetics (Nagata; 2000). The term programmed cell 
death was introduced in 1964, proposing that cell death during 
development is not of accidential nature but follows a sequence of 
controlled steps leading to locally and temporally defined self-destruction 
(Lockshin et al.; 1964). Eventually, the term apoptosis was coined to 
describe the morphological processes leading to controlled cellular self-
destruction and was first introduced in a publication by Kerr, Wyllie and 
Currie (Kerr et al.; 1972). The term Apoptosis is of greek origin, having 
the meaning "falling off or dropping off", in analogy to leaves falling off 
trees or petals dropping off flowers. Described in all multicellular 
eukaryotes (Ellis et al., 1991), apoptosis is an active biological process that 
is implicated in the early development such as during metamorphosis in 
insects and amphibians, organogenesis in virtually all multicellular 
organisms, and has a key role in morphogenesis (Vaux et al.; 1988), in 
sexual differentiation and epigenetic processes of self-organization of the 
immune and nervous system (Ameisen; 2002). Apoptosis also exerts a role 
opposite to mitosis in the maintenance of cell populations. Infact, 
balancing the life/death ratio of damaged cells in the adult, apoptosis 
allows tissue homeostasis (Orrenius et al.; 2003). As examples of this 
cellular altruism, apoptosis plays an active part in the removal of 
interdigital webs in fingers and toes and in the formation of T and B cell of 
the immune system by eliminating nonreactive or self-reactive cells. 
Apoptosis is also a protective mechanism, by directing lysis of virus-
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infected cells, foreign cells or incipient neoplasm. It also plays a central 
role in the immune system. Under physiological conditions, immature 
lymphocytes that bind to autoantigens are eliminated by apoptosis. This is 
thought to protect against immune recognition of ‘self’. Defects in the 
deletion of these lymphocytes predispose to autoimmunity. 
Apoptosis is therefore a regulated process, to which the cell participates 
actively, with a series of events morphologically and biochemically 
repeatable and well-defined (Figure 4). This suicidal pathway is 
characterized by stereotypical morphological changes: the cell shrinks, 
shows deformation and looses contact to its neighbouring cells. Its 
chromatin condenses and marginates at the nuclear membrane, the plasma 
membrane is blebbing or budding, and finally the cell is fragmented into 
compact membrane-enclosed structures, called 'apoptotic bodies' which 
contain cytosol, the condensed chromatin, and organelles. The apoptotic 
bodies are engulfed by macrophages and thus are removed from the tissue 
without causing an inflammatory response. Those morphological changes 
are a consequence of characteristic molecular and biochemical events 
occurring in an apoptotic cell, most notably the activation of proteolytic 
enzymes which eventually mediate the cleavage of DNA into 
oligonucleosomal fragments as well as the cleavage of a multitude of 
specific protein substrates which usually determine the integrity and shape 
of the cytoplasm or organelles (Saraste et al.; 2000). The oligosomal DNA 
fragments result in a distinct laddering pattern on an ethidium bromide-
stained agarose gel that represents a hallmark of apoptosis (Wyllie et al.; 
1980). As a result, cells shrink and condense into multiple small 
membrane-bound named ‘apoptotic bodies’, which display a particular 
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propensity as targets for phagocytes. These removes apoptotic cells 
without leaking the cytoplasmic contents into the intercellular space, 
minimizing tissue inflammation, avoiding damage to neighbouring cells, 
and efficiently degrading host (or viral) DNA. Apoptosis is in contrast to 
the necrotic mode of cell-death in which case the cells suffer a major 
insult, resulting in a loss of membrane integrity, swelling and disrupture of 
cells.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 4. Apoptosis morphological changes. (1) Cell shrinks and chromatin condenses. 
(2) Plasma membrane bebbling. (3) Nucleus fragmentation. (4) Apoptotic bodies 
formation which contain cytosol, the condensed chromatin, and organelles. (5) The 
apoptotic bodies are engulfed by macrophages and thus are removed from the tissue.
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The components of the apoptotic signalling network are genetically 
encoded and ready to be activated by a death-inducing stimulus (Ishizaki et 
al.;1995; Weil et al.; 1996). Apoptosis can be triggered by various stimuli 
from outside or inside the cell, e.g. by ligation of cell surface receptors, by 
DNA damage as a cause of defects in DNA repair mechanisms, treatment 
with cytotoxic drugs or irradiation, by a lack of survival signals, 
contradictory cell cycle signalling or by developmental death signals. 
Death signals of such different origin nevertheless appear to eventually 
activate a common cell death machinery leading to the characteristic 
features of apoptotic cell death. Numerous environmental factors can 
activate cell suicide, and other factors can specifically antagonize 
apoptosis. Activators of apoptosis include tumour necrosis factor α (TNF 
α), Fas ligand (FasL), transforming growth factor ß (TGF ß), Bax (and 
other proapoptotic Bcl-2 family members), and glucocorticoids. In 
addition, aberrant oncogene expression (e.g. c-myc), or normal tumour 
suppressor gene function (such as p53) may trigger apoptosis under 
specific conditions. In many cases, simultaneous conflicting signals for 
growth stimulation and suppression trigger apoptosis. Most growth factors 
exert explicitly antiapoptotic signalling on their target cells. Cytokines 
regulate survival through their receptors, which trigger a cascade of 
intracellular signalling. Among the intracellular (noncytokine) factors 
which showed to suppress apoptosis, there are CD40 ligand, viral genes 
such as E1B from adenovirus, baculovirus p35, and antiapoptotic genes in 
the Bcl-2 family. Several DNAviruses have been demonstrated to encode 
factors which function to curtail the cellular apoptotic response 
(presumably a prerequisite for successful viral infection/ propagation). A 
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few apoptotic modulators, including FasL and TNF, induce apoptosis 
which is largely confined to the development and regulation of the immune 
system.  
The apoptotic process can be divided in three phases: 
-Induction: includes the sending of signals that will trigger apoptosis and 
primary transduction pathways triggered by them. The pro-apoptotic 
signals could be distincted in intrinsic and extrinsic, depending on whether 
they come from the outside environment or within the cell. The intrinsic 
signals interact with transmembrane receptors belonging to the superfamily 
of Tumor Necrosis Factor (TNF) receptors (Locksley et al.; 2001); the 
extrinsic signals instead, cause modifications of the mitochondria, such as 
the decrease in membrane potential and excessive production of radical 
species, with consequent opening of pores in the mitochondrial membrane 
(megachannel or mitochondral pores) and release in the cytoplasm of 
factors normally sequestered in the intermembrane space such as 
cytochrome C (cytC) or AIF (Apoptosis Inducing Factor) (Saelens et al.; 
2004).  
-Execution: during this phase, both extrinsic and intrinsic pathways 
converge in the activation of a class of proteases called caspase (cysteine 
dependent aspartate specific protease), characterized by the presence of a 
cysteine residue in its catalytic site and specificity for substrates containing 
an aspartate residue. The caspases are of central importance in the 
apoptotic signalling network which are activated in most cases of apoptotic 
cell death (Bratton et al.; 2000). So far, 7 different caspases have been 
identified in Drosophila, and 14 different members of the caspase-family 
were described in mammals, with caspase-11 and caspase–12 only 
   Mechanisms of cell death   
 
 75 
identified in the mouse (Denault et al.; 2002; Richardson et al.; 2002). 
Actually, strictly defined, cell death only can be classified to follow a 
classical apoptotic mode if execution of cell death is dependent on caspase 
activity (Leist et al.; 2001). In the cell, caspases are synthesized as inactive 
zymogens, the so-called procaspases; these proteins carry a prodomain at 
their N-terminus followed by a large and a small subunit, which sometimes 
are separated by a linker peptide. Upon maturation, the procaspases are 
proteolytically processed between the large and small subunit, resulting in 
a small and a large subunit. The proapoptotic caspases can be divided into 
the group of initiator caspases including procaspases-2, -8, -9 and –10, and 
into the group of executioner caspases including procaspases-3, -6, and –7. 
Whereas the executioner caspases possess only short prodomains, the 
initiator caspases possess long prodomains, containing death effector 
domains (DED) in the case of procaspases-8 and –10 or caspase 
recruitment domains (CARD) as in the case of procaspase-9 and 
procaspase-2. Via their prodomains, the initiator caspases are recruited and 
activated by death inducing signalling complexes either in response to the 
ligation of cell surface death receptors (extrinsic apoptosis pathways) or in 
response to inner signals originating by the cell (intrinsic apoptosis 
pathways). Furthermore, they are responsible for the activation of effective 
caspases, which guarantee the continuity of the process in its main 
catalytic events (Figure 5). In extrinsic apoptosis pathways, procaspase-8 
is recruited by its DEDs to the death inducing signalling complex (DISC), 
a membrane receptor complex formed following to the ligation of a 
member of the tumor necrosis factor receptor (TNFR) family (Sartorius et 
al.; 2001). When bound to the DISC, several procaspase-8 molecules are 
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near to each other and therefore are assumed to activate each other by 
autoproteolysis (Denault et al.; 2002). Intrinsic apoptosis pathways involve 
procaspase-9 which is activated downstream of mitochondrial proapoptotic 
events; the release of cytochrome c from mitochondria induced the 
formation of the so called apotosome, a cytosolic death signalling protein 
(Salvesen et al.; 2002b). In this case there is the dimerization of 
procaspase-9 molecules at the Apoptotic-proteaseactivating-factor-1 
(Apaf-1) scaffold that is responsible for caspase-9 activation (Denault et 
al.; 2002). Once the initiator caspases have been activated, they can 
proteolytically activate the effector procaspases-3, -6, and -7 which 
subsequently cleave a specific set of protein substrates, including 
procaspases themselves, resulting in the mediation and amplification of the 
death signal and eventually in the execution of cell death with all the 
morphological and biochemical features usually observed. 
-Phagocytosis: the membrane of the apoptotic bodies exposes molecules 
such as phosphatidyl-serine, normally located in the cytosolic layer, on the 
surface (Bratton et al.; 2000), or calreticulin (Gardai et al.; 2005), which 
are recognized by specific receptors present on macrophages cell surface, 
marking the beginning of phagocytosis.  
   Mechanisms of cell death   
 
 77 
 
 
 
Figure 5.  Schematic representation of apoptotic activation. The pro-apoptotic signals 
could be distincted in intrinsic and extrinsic; both extrinsic and intrinsic pathways 
converge in the activation of caspases. 
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3.1.1 Regulatory mechanisms in apoptosis signalling 
Commonly, the activation of apoptosis is regarded to occur when a cell 
encounters a specific death-inducing signal such as the ligation of a death 
receptor by its analogous ligand or if cells are treated with a cytotoxic 
drug. This suggests that the apoptosis signalling pathways in viable cells 
occur in response to a death stimulus. At the same time, cell death is 
continously repressed by survival signals such as provided by other cells of 
the organism, e.g. growth factors, hormones, nutrients, adhesion 
molecules. Those survival signals enhance the expression and/or activity of 
antiapoptotic regulatory molecules thereby keeping in check the activation 
of proapoptotic factors (Raff et al.;1993; Ameisen; 2002).  
The main protagonists of this modulation are proteins belonging 
respectively to the Bcl-2 and p53 families respectively. 
-Bcl 2 family: 22 members of Bcl-2 family (B-cell lymphoma gene 2) have 
been identified. They were classified on the basis of preserved helix 
sequences, known as homology domains Bcl-2 (BH, Bcl-2 Homology 
domains) (Scorrano & Korsmeyer; 2003) (Figure 6). In addition, there are 
a number of other prosurvival proteins, e.g. Bcl-XL, Bcl-w, A1, and Mcl-
1, which all possess the domains BH1, BH2, BH3, and BH4. The 
proapoptotic group of Bcl-2 members can be devided into two subgroups: 
the Bax-subfamily consists of Bax, Bak, and Bok that all possess the 
domains BH1, BH2, and BH3, whereas the BH3-only proteins (Bid, Bim, 
Bik, Bad, Bmf, Hrk, Noxa, Puma, Blk, BNIP3, and Spike) have only the 
short BH3 motif, an interaction domain that is both necessary and 
sufficient for their killing action (Cory et al.; 2002; Mund et al.; 2003). The 
pro-apoptotic elements block the action of anti-apoptotic proteins (Bcl-2, 
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Bcl-XL) or activate the pro-apoptotic proteins Bax and Bak (Ward et al.; 
2004). The proteins of this family have a location dependent from the role 
played. The anti-apoptotic elements Bcl-2 and Bcl-XL are located above 
the membranes of the organelles (endoplasmic reticulum, nucleus and 
outer membrane of the mitochondria). Bax, instead, is mainly located in 
the cytoplasm, anchored to the cytoskeleton structures (Desagher & 
Martinou; 2000). Apoptotic stimuli, discovering the C-terminal 
hydrophobic residue, determine the dimerization of Bax that can, therefore, 
interfere with the lipids of the Bax external mitochondrial membrane (Fig. 
7). It follows the fall of the mitochondrial potential ( m) and the release 
of not only molecules like Smac/ Diablo, which inactivated caspase 
inhibitors, but also of calcium ions, free radicals and glutathionees, 
responsible of the amplification of the signal. On the other hand, Bax and 
Bak can act on the endoplasmic reticulum by controlling calcium 
homeostasis (Scorrano L & Korsmeyer SJ; 2003). Finally, it must be 
remembered that mitochondria are involved by apoptosis even when the 
signal starts from the receptors of membrane, since caspase initiator 8 
determines the cleavage of Bid, a pro-apoptotic modulator, which is 
located on this organelle (Figure 7). This is an example of ''crosstalk'' 
among the receptor and mitochondrial pathways (Elmore et al.; 2007). 
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Figure 6. Structure of the members of the Bcl-2 family members. TM: transmembrane 
domain (Martin & Vuori, 2004). 
 
 
Figure 7. Mechanism of action of pro-apoptotic proteins belonging to the Bcl-2 family 
(Desagher & Martinou, 2000).
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-P53: the coding gene for p53 protein is an oncosuppressor, the whose 
main role is to prevent inappropriate proliferation of cells in response to 
DNA damage. Activated p53 can cause arrest, depending on the 
circumstances, of the cell cycle in G1 or apoptosis. 
The induction of programmed cell death is dependent on or less from 
transcriptional activity (Moll & Zaika; 2001) (Fig. 9). In the first case, p53 
activates transcription of death receptors (DR5, CD95, Fas), proapoptotic 
proteins of the Bcl-2 family (Bax, PUMA, NOXA, Bid), as well as 
apoptotic adapters such as Apaf-1. Furthermore, p53 represses the 
transcription of anti-apoptotic proteins such as Bcl-2 and Bcl-XL (Sionov 
& Haupt; 1999). If the induction is independent from the transcription, p53 
could act as a sensitizer of apoptosis, like Bad and Bik, linking directly to 
Bcl-2 and Bcl-XL and then activating only indirectly Bak and Bax (Mihara 
et al.; 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Apoptosis induction by p53. 
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3.1.2 Viral infection and apoptosis 
Apoptosis plays an important role in cellular response to different insults, 
including viral infections. The virus-induced apoptosis, associated with a 
significant decrease in the number of viral progeny production, was first 
described in cells infected with a mutant adenovirus (Pidler et al.; 1984). 
Subsequently, several studies support the theory according to which 
programmed cellular death represents an innate defense mechanism against 
infections; through premature cell lysis the host blocks viral replications 
(Clem et al.; 1991; Koyama et al.; 1998). There are many interactions 
between virus and apoptosis; the virus-induced apoptosis is considered a 
host mechanism of defense since it allows phagocytosis of infected cells 
reduced to apoptotic bodies, restricting inflammatory response and 
stimulating the specific immune responses (Vaux et al.; 1994). However, 
the relationship between viruses and host cells is a classic conflict of 
interest, where the cell tries to minimize the damage of the infection while 
the virus tries to get the most benefit from the cell replication apparatus 
(Krakauer & Payne; 1997). Viruses, in fact, can influence the apoptotic 
process triggering the signal transduction until programmed cellular death 
(for example TNF receptor) or, sometimes, they have genes or proteins 
that act the action of apoptotic regulatory molecules. Sometimes apoptosis 
represents a favourable mechanism for virus since programmed cell death 
promotes, after the assembly, the spread of virions within apoptotic bodies 
or associated to them (Mi et al.; 2001). The ability to inhibit apoptosis is, 
however, necessary to prevent premature death of host cells, to facilitate 
spread of viral progeny in lytic infections and to allow persistent infection 
(Shen & Shenk; 1995). Several studies have investigated the cell 
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sensitivity to the first phases of infections (adsorbition and virus entry) and 
have observed the proapoptotic nature of some virion structural proteins.  
Evaluating Herpesvirus, it was showed that modulation of apoptosis 
through virus-encoded proteins is the key to the pathogenesis of infection 
(Longo et al.; 2009; Pagnini et al.; 2005; Wang et al.; 1997). The induction 
of programmed cell death by HSV represents an early event related to the 
expression of an IE gene or of a structural protein introduced into the 
infected cell (Leopardi & Roizman; 1996). If protein synthesis is inhibited, 
apoptosis does not occur. However, apoptosis is "suppressed" by the action 
of some anti-apoptotic viral genes (Koyama et al.; 1998) that interfere 
specifically with a protein kinase, PKR (dsRNA-dependent serine / 
threonine protein kinase) which normally does not only act as a mediator 
of the interferon antiviral functions, but it also induces apoptosis through 
the activation of the death domain associated with FAS (FADD) (Ubol et 
al.; 1994). It was demonstrated the bond between virus and death receptors 
belonging to the family Fas/TNF (Ashkenazi & Dixit; 1998; Schwarz; 
1996). BHV-1 induced apoptosis through a structural constituent of virion 
which acts as a ligand for death receptors, since apoptosis was observed in 
cells exposed to inactivated virus. Furthermore, programmed cell death 
induced by BHV-1 can be considered a late event, since it occurs during 
the last stages of infection (Devireddy & Jones; 1999).  
Often apoptosis is the basis of the pathogenetic mechanisms of different 
infections and also herpetic infections (Shen & Shenk; 1995; Teodoro & 
Branton; 1997). It was demonstrated the capacity of CpHV-1 of inducing 
apoptosis in mononuclear cells of sheep blood (Pagnini et al.; 2005); it was 
also demonstrated the proapoptotic potential of CpHV-1 in permissive 
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cells of the MDBK line (Longo et al.; 2009) and in neuroblastoma cell line 
(Neuro 2A) (Montagnaro et al.; 2013).  
 
3.2. Autophagy (PCD II) 
Autophagy is a lysosomal degradative mechanism occurring in different 
modes (chaperone-mediated autophagy, microautophagy, and 
macroautophagy) (Cuervo; 2004) (Figure 9). The discovery of autophagy 
by De Duve and Wattiaux (De Duve et al.; 1966) was contemporary with 
that of lysosomes. The physiological importance of autophagy in 
maintaining cell homeostasis in organs such as liver and in cultured cells 
rapidly emerged (Mortimore et al.; 1977; Mortimore et al.; 1994). At the 
same time, the term autophagic cell death or type II programmed cell death 
(PCD II) was introduced to describe a cell death different from apoptosis 
or type I PCD (PCD I) (Schweichel et al.; 1973; Clarke et al.; 1990).  
Autophagy is a general and evolutionarily conserved vacuolar catabolic 
pathway terminating in the lysosomal compartment (Seglen et al.; 1992; 
Klionsky et al.; 2000). It contributes to the quality control of cytoplasmic 
components by recycling macromolecules (autophagy is responsible for 
the turnover of long-lived proteins) and removing organelles when 
damaged or in excess (peroxisomes, mitochondria). It enables cells to 
survive stress from the external environment, such as nutrient deprivation, 
as well as internal stresses like accumulation of damaged organelles and 
pathogen invasion. Autophagy is induced by starvation in all eukaryotic 
systems examined, including several species of fungi, plants, slime mold, 
nematodes, fruit flies, mice, rats and humans (Levine et al.; 2004). It aids 
in maintenance of homeostasis in cellular differentiation, tissue 
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remodeling, growth control (Tanida et al.; 2004; Meijer et al.; 2004). 
Several types of autophagy exist, which differ mainly in the site of cargo 
sequestration and in the type of cargo. These include micro- and 
macroautophagy, chaperone-mediated autophagy, micro- and 
macropexophagy, piecemeal microautophagy of the nucleus, and the 
cytoplasm-to-vacuole targeting (Cvt) pathway (Klionsky; 2004) (Figure 9). 
This process involves the sequestration of bulk cytoplasm within a 
cytosolic double-membrane vesicle termed the autophagosome, which 
ultimately fuses with the lysosome (or the vacuole in yeast). The 
delimiting membrane of the autophagosome is derived from an ‘isolation’ 
membrane or phagophore of unknown origin (Fengsrud et al.; 1995). 
Fusion results in the release of the inner vesicle, now termed an autophagic 
body, into the lysosome lumen. Within the lysosome the engulfed material 
is denatured because of the acidic environment.and the products are 
recycled. Microautophagy is the way used to remove cellular organelles no 
more useful for the turnover of basal epithelial cells.  
Macroautophagy is a homeostatic way, divided into several steps, of 
extensive catabolism against older proteins and cellular organelles that are 
identified by the lysosomes and then, destroyed (Levine et al.; 2005; 
Levine et al.; 2008). Autophagy si mediated by chaperone proteins (CMA), 
a group of polypeptides (the main being hsc 70) that binds the soluble 
cytoplasmic proteins and makes them recognizable to the lysosomes and 
thus eliminates them. This is the only destructive way in mammals against 
cytoplasmic proteins. Autophagy has been implicated in several human 
diseases and conditions, including cancer, neurodegenerative disorders, 
certain myopathies, aging and defense against pathogens. Identification of 
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its molecular machinery and signaling pathways has shed some light on the 
importance of autophagy in physiological processes and diseases 
(Klionsky et al.; 2000; Cuervo et al.; 2004; Levine et al.; 2004). 
 
 
 
 
Figure 9. Schematic representation of autophagy. 
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3.2.1 Morphology and mechanistic aspects of Autophagy 
At least 30 genes (ATGs) were identified in yeast that function in the 
regulation and execution of autophagy (Xie et al., 2007). Some of these 
genes are known homologous in mammalian cells. Classical autophagy can 
be subdivided into four main phases that are performed by specific ATG 
genes (Levine et al.; 2008; Xie et al.; 2007). Among the autophagy-related 
(ATG) genes, discovered in yeast and almost integrally conserved in all 
eukaryotic phyla, which control the formation of the autophagosome 
(Klionsky et al.; 2003), beclin 1 (the mammalian ortholog of the yeast 
ATG6) is a tumor suppressor gene that contributes with the class III 
phosphatidylinositol-3- kinase (PI3K) to the formation of the 
autophagosome (Liang et al.; 1999; Kihara et al.; 2001). Other tumor 
suppressor gene products, such as p53, PTEN, TSC1/TSC2, death-
associated protein kinase (DAP kinase), are involved in the control of 
autophagy (Botti et al.; 2006). Interestingly, autophagy is also stimulated 
in cancer cells by ceramide (Scarlatti et al.; 2004; Daido et al.; 2004), a 
tumor suppressor lipid (Hannun et al.; 1993). 
Although autophagy is a dynamic process, the pathway was delineated into 
several static steps for the convenience of description: induction and 
nucleation, phagophore expansion, autophagosome targeting, docking and 
fusion, and cargo degradation and recycling.  
Many signaling pathways and proteins seem to be involved in this first 
phase, but the esact mechanism of action and/or interaction is unknown. 
Autophagy may be induced as a response to a change in the extracellular 
environment of a cell, and the target of rapamycin complex 1 (TORC1) is 
one of the signaling pathways that plays a primary role in sensing the shift 
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in nutrient availability. Nutrient starvation, in particular nitrogen and/or 
amino acid limitation, initiates an intracellular signalling cascade by 
discontinuing TORC1 stimulation, resulting in the activation of the Atg1 
kinase complex. The Atg1 kinase complex works directly downstream of 
the TORC1 pathway and it consists of Atg1, Atg13, and a scaffold 
subcomplex that includes Atg17- Atg31-Atg29 (Kamada et al.; 2000). 
Assembly of this complex is crucial for autophagy because it plays a role 
in recruiting other Atg proteins to the phagophore assembly site (PAS) and 
activating downstream targets through phosphorylation (Suzuki et al.; 
2007; Papinski et al.; 2014). Protein kinase A (PKA) is another negative 
regulator of the Atg1 kinase complex, in this case primarily in response to 
carbon source, whereas the energy sensor Snf1/AMP-activated protein 
kinase (AMPK) acts as a positive regulator. Although the associations 
among these proteins have been demonstrated as biomolecular 
interactions, it is unknown whether all of these proteins are ever present in 
a single complex. In autophagy, nucleation refers to the process of 
mobilizing a small group of molecules to the PAS; the phagophore is the 
active sequestering compartment of autophagy. The class III PtdIns3K 
complex I, which is employed specifically for autophagy, is one of the key 
complexes that are recruited to the PAS upon induction of autophagy. This 
complex is constituted of five distinct proteins: the lipid kinase Vps34, the 
regulatory kinase Vps15, Vps30/Atg6, Atg14 and Atg38, which are all 
necessary for autophagy (Schu et al.; 1993; Kihara et al.; 2001). In brief, 
the class III PtdIns3K is responsible for the production of 
phosphatidylinositol-3-phosphate (PtdIns3P) directly from 
phosphatidylinositol (Burman et al.; 2010). This PtdIns3P is important for 
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the correct localization of some of the Atg proteins including Atg18 and 
Atg2, which enables the recruitment of Atg8, Atg9 and Atg12 to the PAS 
(Obara et al.; 2008). Other proteins and molecules that play a role in 
regulating this first autophagic phase are p53, c-jun-N-terminal kinase1 
(JNK1), eucariotic initiation factor 2α (elF2α), GTPase and intracellular 
calcium (Levine et al 2008; Talloczy et al.; 2009;). All these molecules 
and/or signaling pathways appear to promote autophagy by activating class 
III PtdIns3K Cps3, which promotes the formation of phosphatidylnositous 
3-phosphate (PIP3) on lipids. Autophagosomes, which correspond to the 
mature form of the phagophore, is essentially a terminal compartment that 
does little more than fuse with the vacuole; formation of the phagophore 
and sequestration by the phagophore are the truly dynamic steps of 
autophagy (Baba et al.; 1994). There are two essential ubiquitin-like (Ubl) 
conjugation systems that are necessary for phagophore expansion and 
these involve the Ubl proteins Atg12 and Atg8 (Ohsumi; 2001); these two 
proteins have structural similarity to ubiquitin, but are not actual 
homologs. Atg12 is conjugated to Atg5 via the action of the E1 and E2 
enzymes Atg7 and Atg10, and this conjugate binds Atg16 to form the 
dimeric Atg12–Atg5–Atg16 complex; Atg8 undergoes a different type of 
conjugation, being covalently attached to the lipid phosphatidyl-
ethanolamine (PE). The generation of Atg8–PE involves the protease 
Atg4, Atg7 as an E1 enzyme and Atg3 as an E2 enzyme, with the Atg12–
Atg5–Atg16 complex participating as an E3 enzyme, although the latter is 
not absolutely required for conjugation to occur (Cao et al.; 2008). A 
detailed mechanism in which these conjugation systems operate along with 
other complexes to enlarge the phagophore is currently an on-going 
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research topic. Atg9 functions in some manner as the membrane 
transporter for the growing phagophore, but direct evidence or a 
mechanistic explanation are not available. Nonetheless, Atg9 has multiple 
functions; first, Atg9 is the only transmembrane protein that is essential for 
phagophore expansion (Noda et al.; 2000); second, Atg9 is found to be 
highly mobile in the cytosol upon rapamycin treatment (Yamamoto et al.; 
2012); third, this protein is capable of binding with itself and appears to 
transit to the PAS as part of a complex (Reggiori et al.; 2005). While none 
of these studies directly proves the role of Atg9 in membrane shuttling, 
researchers have begun identifying the machinery that is involved in Atg9 
trafficking. Upon completion of the autophagosome, it fuses with the 
vacuole. This fusion allows the release of the inner autophagosome vesicle 
into the vacuole lumen where it is now termed an autophagic body. Note 
that mammalian cell lysosomes are generally smaller than autophagosomes 
so autophagic bodies are not a general feature of autophagy in most of the 
more complex eukaryotes. The mechanism that controls the fusion is 
unknown at present; however, there are regulatory mechanisms to prevent 
premature autophagosome fusion with the vacuole, which would prevent 
delivery of the cargo into the vacuole lumen. Other cellular processes that 
also deliver their cargo to the vacuole employ similar components that 
facilitate fusion including SNARE (SNAP= Soluble NSF Attachment 
Protein Receptor) proteins and those involved in the homotypic fusion and 
vacuole protein sorting (HOPS) pathway (Jiang et al.: 2014). After the 
cargo is delivered inside the vacuole, the autophagic body membrane is 
degraded by a putative lipase, Atg15, (Epple et al.; 2001; Teter et al.; 
2001) followed by cargo degradation by resident hydrolases. Once 
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degraded, the resulting macromolecules (aminoacids, proteins and lipids) 
are released back into the cytosol through various permeases including 
Atg22 (Yang et al.; 2006).  
 
 
 
 
 
Figure 10. Regulatory mechanisms of autophagy. (http://www.biochemsoctrans.org). 
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3.2.2 Viral infection and autophagy  
Different studies demonstrated an interaction between viral infection and 
autophagy (Kirkegaard et al.; 2004; Deretic et al.; 2009). Some viruses can 
modulate autophagy; Furaka et coll. have analysed the role of autopaghy in 
oncolytic herpes simplex virus type 1-induced cell death in squamous cell 
carcinoma cells (Furaka et al.; 2017).  Montagnaro et coll. have 
demonstrated the impact of BHV-4 infection on autophagy in BHV-4 
infected Madin Darby bovine kidney (MDBK) cells, suggesting that the 
virus developed mechanisms for modulation of autophagy, probably to 
enhance viral replication and to evade the immune system (Montagnaro et 
al.; 2013). Autophagy protects host cells from infection activating the virus 
degradation through auto-lysosomies or triggering innate immune response 
(Talloczy et al.; 2006; Delgado et al.; 2008). It was demonstrated that 
autophagy can have a dangerous effect on the pathogenesis of virus 
Sindbis (Li et al.; 2005). Autophagy is also implicated in the adaptive 
immune responses later viral infection providing viral antigens to MCH I 
and II (Paludan et al.; 2005; English et al.; 2009; Gannage et al.; 2009). 
Some viruses demonstrated different strategies to antagonize autophagy 
triggered by host cells (Cavignac et al.; 2010).   
  
3.3 Necrosis  
Necrosis is a passive, catabolic, pathological cell death process which 
generally occurs in response to external toxic factors such as inflammation, 
radiations, viral infections, immune responses, ischaemic or toxic injury 
(Dive et al.; 1992). Necrosis is characterized by the swelling of 
mitochondria, early break of the plasma membrane, dispersed chromatin 
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and early destruction of the intact structure of the cell. During necrosis, the 
cellular contents are released uncontrolled into the cell environment which 
results in damage of surrounding cells and a strong inflammatory response 
in the corresponding tissue (Leist et al.; 2001). As such, necrosis is often 
detected in infections and inflammatory diseases. This association has led 
to the popular view that necrosis represents pathological cell death. Recent 
advances have showed the existence of dedicated molecular pathways 
controlling necrotic cell death. Notably, the classical markers that define 
apoptosis can sometimes be detected in necrosis. For example, Annexin V 
staining is a commonly used method to detect exposure of phosphatidyl 
serine (PS) on the outer leaflet of the plasma membrane in early apoptotic 
cells. In some necrotic cells, PS exposure can be detected without 
significant plasma membrane leakage (Sawai et al.; 2001). PS exposure is 
supposed to mark apoptotic cells for clearance by phagocytes. However, 
researchers have also described scavenger receptors that recognize necrotic 
cells (Yamasaki et al.; 2008; Sancho et al.; 2009). Recent studies have 
identified several forms of regulated necrosis, including phosphoribosyl 
pyrophosphate (PPRP)-1-mediated necrotic death (Yu et al.; 2002), p53-
mitochondrial function–mediated necrosis (Vaseva et al.; 2012), pyroptosis 
(Cookson et al.; 2001), ferroptosis (Gao et al.; 2015) and necroptosis 
(Moriwaki et al.; 2015). Thus, caspase-dependent apoptosis is not the only 
form of programmed cell death. Necroptosis has recently gained increasing 
attention as a novel but well-studied form of programmed cell death. 
Degterev et coll. (Degterev et al.; 2005), who originally coined the term 
“necroptosis,” showed that necroptosis is characterized by a necrotic cell 
death morphology and by activation of autophagy. This form of 
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programmed cell death can occur when the cells suffer from severe stress 
or are treated with chemotherapy or inflammatory factors (Chan et al.; 
2003; Long et al.; 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Morphological representation of necrosis. (https://www.studyblue.com). 
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The first discovery of necroptosis can be tracked to the 1988 observation 
that tumor necrosis factor (TNF) triggers necrotic death in multiple cell 
types (Laster et al.; 1988). For a long time, it was believed that this type of 
TNF-triggered cell death was apoptosis. In 1998, Vercammen et al. 
reported that TNF induced the rapid death of murine L929 fibrosarcoma 
cells in a necrotic manner when cellular caspases were repressed by 
inhibitors. Around the same time, Kawahara et coll. observed that Fas-
associated protein with death domain (FADD)-mediated cell death was 
independent of caspase-8 activation. These studies suggested that the 
apoptosis-related molecules regulated a novel form of cell death that was 
different from apoptosis and more similar to necrosis. This novel finding 
motivates investigators to explore the potential mechanism behind it. A 
landmark study of necroptosis was published in 2000 when receptor-
interacting protein kinase 1 (RIP1) was identified as the critical regulator 
of necrotic death in caspase-inhibited cells (Holler et al.; 2000). In 2005, 
Degterev et al. (Degterev et al.; 2005) called this Fas/TNF receptor 
(TNFR) receptor family-triggered, nonapoptotic form of cell death 
“necroptosis” and invented a small molecule, necrostain-1, that blocked 
necroptosis. In 2009, three independent studies proved that RIP3 was 
required for necroptosis and was the downstream target of RIP1 (Cho et 
al.; 2009; Zhang et al.; 2009). In 2012, mixed lineage kinase domain–like 
protein (MLKL) was identified as a necroptosis executor, which 
functioned after interacting with and being phosphorylated by RIP3 at its 
threonine 357 and serine 358 residues (Sun et al.; 2012). The discovery of 
MLKL enabled a rough mapping of the necroptosis regulatory pathway. 
As with apoptosis, the goal of necroptosis is to eliminate unnecessary or 
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abnormal cells from the body. This is important for embryonic 
development and disease defenses. Cancer is a disease that is closely 
related to cell death, and resistance to cell death is a hallmark of cancer. As 
one of multiple forms of cell death, necroptosis has been recognized for its 
critical roles in defending against cancer. Numerous studies have 
suggested that necroptosis suppresses the initiation and progression of 
cancer and facilitates its therapy. The anti-tumor effects of necroptosis 
have been recently reviewed (Chen et al.; 2016). However, emerging data 
have revealed that necroptosis can promote cancer progression, which 
suggests that necroptosis is a double-edged sword in cancer progression. 
 
 
Figure 12. Activation of necroptosis process. (www.cell.com). 
 
 
   Mechanisms of cell death   
 
 97 
3.3.1 Viral infections and necrosis 
Necroptosis can be initiated following viral infection by externaland 
internal stimuli, including activators of cell death receptors, viral nucleic 
acids, and direct sensing of viral proteins. TLRs that sense viral nucleic 
acids (TLR3, TLR7, TLR9) induce necroptosis upon ligand binding and 
caspase-8 inhibition, but these receptors elicit this response via different 
mechanisms. For example, similarly to apoptosis, only TLRs that rely on 
TRIF (i.e., TLR3) promote necroptosis through an intrinsic mechanism 
(Kaiser et al.; 2010; He et al.; 2011). TLRs induce necroptosis indirectly 
through the expression of TNF-α (Kaiser et al.; 2010). While TNFR 
signalling is normally associated with apoptosis, this receptor can also 
induce necroptosis under conditions of caspase-8 inhibition. When 
caspase-8 is inhibited, TNFR signalling induces the formation of a protein 
complex known as the necrosome, which includes the RIPK family 
members RIPK1 (Holler et al.; 2000) and RIPK3 (Cho et al.; 2009).  The 
strongest argument for an antiviral role of TNFR-mediated necroptosis 
derives from studies of vaccinia virus (VV). VV encodes the B13R protein 
which blocks caspase-8 activity and sensitizes infected cells to TNF-α-
mediated necroptosis in vitro (Zhang et al.; 2009). Interestingly, no viral 
infection has been shown to induce TLR3-dependent necroptosis in vitro, 
and elucidation of the necroptotic signalling pathway initiated by TLR3 
has been performed solely through use of synthetic RNAs that mimic viral 
nucleic acids (Kaiser et al.; 2010; He et al.; 2011). Influenza A virus (IAV) 
infection induces cell death in MEF sand human lung epithelial cells via a 
DAI/RIPK3-dependent signalling axis (Kuriakose et al.; 2016). Viral 
nucleic acids can initiate necroptosis in response to DNA and RNA virus 
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infection. RIPK3 has also been shown to promote cell death-independent 
neuroinflammation following subcutaneous West Nile virus (WNV) 
infection (Daniels et al.; 2017). 
The ability of viral proteins, rather than viral nucleic acids, to initiate 
necroptosis was first demonstrated in response to HSV infection. HSV-1 
and HSV-2 induce necroptosis in murine cells, and the viral RHIM 
domain-containing proteins ICP6 (HSV-1) and ICP10 (HSV-2) mediate 
this response (Wang et al.; 2014; Huang et al.; 2015). However, in contrast 
to observations made in murine cells, HSV does not induce necroptosis in 
human cells. Simultaneously, these viral proteins bind to and inactivate 
caspase-8, indicating HSV can directly antagonize apoptosis and 
necroptosis through a single viral protein. Furthermore, these observation 
ssuggest that necroptosis may represent a species-specific barrier to 
HSVinfections (Guo et al.; 2015). 
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4. Aim of the study 
Oncolytic virus immunotherapy is a therapeutic approach to cancer 
treatment that utilizes native or genetically modified viruses that 
selectively replicate within tumour cells while displaying minimal adverse 
effects in normal healthy cells. In recent years, virus therapy has become a 
promising prospect for the treatment of cancer, particularly in the cases 
where traditional approaches are not feasible or are unlikely to succeed. 
The ability of viruses to kill cancer cells has been recognized for nearly a 
century, but only over the past decade have clinical trials documented a 
therapeutic effect in the treatment of malignancies. The mechanisms 
through which oncolytic viruses mediate tumour rejection are incompletely 
understood. To date, a wide variety of viruses have been evaluated for their 
oncolytic potential, including DNA viruses such as herpesviruses, 
adenoviruses, and vaccinia virus and RNA viruses such as reoviruses and 
poliovirus. HSV-1 vectors have generated much interest in the field, as 
HSV-1 was the first virus used to show that a genetic mutation could 
render a virus oncolytic. To date, Phase I and II clinical trials have been 
conducted with various HSV-1 mutants, showing the safety of 
administering various oncolytic mutants of HSV-1 in humans. However, 
HSV-1 is a human pathogen, so it must be genetically manipulated to 
attenuate the virus sufficiently for it to preferentially replicate in tumor 
cells; attenuation makes viral replication less efficient, compromising the 
success of the therapy.  Furthermore, it has been estimated that 40–90% of 
the population has preexisting immunity to HSV-1, which precludes 
efficient systemic delivery of HSV-1 oncolytic vectors. Consequently, the 
use of wild-type viruses that are not human pathogens is being developed 
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as an alternative approach for oncolytic virotherapy. Exploiting the 
correlation between the members of Alphaherpesvirinae family, we aim to 
investigate the potential of Caprine Herpesvirus 1 (CpHV‐1) as an 
oncolytic vector. Like herpes simplex virus 1 (HSV‐1), the prototype 
member of Alphaherpesvirinae family, CpHV‐1 establishes life‐long, non-
productive latent infections in ganglionic sensory neurons. Our research 
group previously demonstrated that CpHV‐1 has the capacity to induce 
apoptosis in goat peripheral blood mononuclear cells; moreover, we have 
investigated on the pro‐apoptotic potential of CpHV‐1 in a permissive cell 
line (Madin Darby bovine kidney cells, MDBK). Recently, we have 
characterized in more detail the intracellular pathway by which CpHV‐1 
induce apoptosis by analyzing the gene expression response during the 
apoptotic phase of CapHV‐1 infection in a murine neuroblastoma cell line 
(Neuro 2A). Thus, the aim of this study is to investigate the ability of 
CapHV-1 to replicate, cause cytopathic effects and affect cellular viability 
in a panel of human cancer cells lines (HeLa, U2OS, MDAMB-468, A549, 
PC3, K562) from a variety of histological origins. In a first series of 
experiment we have analyzed the effect of CpHV‐1 infection on cell 
viability at different time post infection (p.i.) and several multiplicity of 
infection (MOI). Then, we investigated virus induced cytotoxicity, 
viability, and apoptosis. The final results of this study will allow to 
demonstrate the effect of CpHV‐1 infection in neoplastic cell lines in terms 
of caspase activation and apoptosis modulation, to suggest CpHV-1 as a 
novel candidate oncolytic virus. 
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5.  Material and methods 
5.1 Cell lines 
All cell types were maintained at 37°C with 5% CO2 in medium 
supplemented with 2 mM L-glutamine, 100 U penicillin and 100 U 
streptomycin and were purchased from the American Type Culture 
Collection (ATCC Manassas, VA). Human breast adenocarcinoma (MDA-
MB-468), Human cervical adenocarcinoma (HeLa), Human osteosarcoma 
(U2OS), Human prostatic adenocarcinoma (PC3) were maintained in high 
glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% FBS, Human lung carcinoma (A549) were cultured in F-12K 
Medium supplemented with 10% FBS, and Chronic Myelogenous 
Leukemia (K562) cell lines were maintained in Iscove medium (IMDM) 
(Gibco, Carlsbad, CA, USA). Madin Darby bovine kidney (MDBK) cell 
lines were maintained in DMEM supplemented with 10% FBS and used as 
control. 
 
5.2 Viruses 
The reference Swiss strain E/CH (Mettler F, et al.; 1979) of CpHV-1 was 
used. It was multiplied on MDBK, and cell extracts, obtained by three 
cycles of freezing and thawing, was be pooled, collected, and stored in 
aliquots at -80°C. Infectivity titres was expressed as median tissue culture 
infectious doses (TCID 50)/ml (Reed and Muench, 1938). 
   Material and methods 
 104 
5.3 Cytopathic effect assay 
Before investigating the oncolytic capacity of CpHV-1, we first confirmed 
the restriction of selected human cancer cells against CpHV-1 replication 
and cytopathic effect (CPE) induction. A panel of six cell types (HeLa, 
U2OS, MDAMB-468, A549, PC3 and K562) were infected with 
increasing amounts of CpHV-1, and CPE was monitored. MDBK cell line 
was used as control.  
Briefly, for adherent cells, 90 – 95% confluent cell monolayers were 
infected with a different multiplicity of infection (MOI) between 0,5 and 
10 in serum free medium. After 1 hour of viral adsorption at 37°, cell 
monolayers were maintained in medium with 5% of FBS. At 24, 48 and 72 
hours post infection cells were fixed in methanol and stained with Giemsa 
to observe and score CPE.  
Otherwise for K562 suspension cell, to assess cell viability trypan blue 
assay was performed. Briefly, cells were collected and an aliquot of the 
cell suspension was mixed with an equal volume of 0.2% Trypan-blue 
(Sigma, St. Louis, MO) in 1X phosphate-buffered saline (PBS). After 10 
min, cells were counted using TC20 automated cell counter (Biorad).  
 
5.4 Viability 
Virus viability was assayed by means of the 3-(4,5-Dimethylthiazol-2yl)-
2,5-diphenyl tetrazolium bromide (MTT) (Sigma) assay as previously 
described (Pagnini et al.; 2004). The principle of this method is that MTT, 
a soluble tetrazolium salt, is converted to insoluble formazan by active 
mitochondrial dehydrogenases of living cells. Such conversion from 
yellowish soluble tetrazolium to purple formazan can be assayed 
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spectrofluorimetrically. MTT was added to cultured cells at different hours 
p.i. Cultures were incubated for an additional 2 hours, the medium was 
removed and replaced with dimethyl sulfoxide (DMSO) to solubilise the 
MTT formazan crystals. The spectrophotometer adsorbance at 570 nm was 
determined. 
Data are presented as a percentage of the control, and results are the mean 
± SD of three experiments performed in duplicate. 
 
5.5 Apotox‐glo™triplex assay 
The ApoTox‐Glo™Triplex assay was used to assess viability, cytotoxicity, 
and caspase activation events within a single assay well. In the first part of 
the assay, it measures two protease activities simultaneously; one is a 
marker of cell viability and the other is a marker of cytotoxicity. Peptide 
substrate (glycylphenylalanyl‐aminofluoro‐coumarin; GF‐ FC) enters 
intact cells where it is cleaved by the live‐cell protease activity to generate 
a fluorescent signal proportional to the number of living cells. This 
live‐cell protease becomes inactive upon loss of cell membrane integrity 
and leakage into the surrounding culture medium. Peptide substrate 
(bis‐alany‐lalanyl‐phenylalanyl‐rhodamine 110; bis‐AAF‐R110) is used to 
measure dead‐cell protease activity, which is released from cells that have 
lost membrane integrity. Bis‐AAF‐R110 is not cell‐permeable, so no signal 
from this substrate is generated by intact, viable cells. The live‐ and 
dead‐cell proteases produce different products, AFC and R110, which have 
different excitation and emission spectra, allowing them to be detected 
simultaneously. In the second part of the assay, the Caspase Glo® 3/7 
Reagent (Promega Corporation), add in an “add‐mix‐measure” format, 
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results in cell lysis, followed by caspase cleavage of the substrate and 
generation of a “glow‐type” luminescent signal produced by luciferase. 
Human cancer cells of approximately 500/well were seeded in a flat 
96‐well micro‐plate (Becton Dickinson Labware, USA) as triplicates. Four 
different types of controls, namely: positive, infected, negative, and 
background controls were used throughout the study. Positive control had 
cells with culture medium treated with Staurosporine of 10 mM final 
concentration for 24 h to induce apoptosis. Infected cell cultures contained 
cells treated with CapHV‐1 at MOI 2.5 for 24. Negative control consisted 
of mock infected neoplastic human cells and no‐cell control (background) 
containing only culture medium without cells. After 24 h post‐infection 20 
µl of viability/cytotoxicity reagent containing both GF‐AFC and 
bis‐AAF‐R110 substrates was added to each well and briefly mixed by 
orbital shaking at 300–500 rpm for 30 s and then incubated at 37°C for 30– 
180 min. Fluorescence was measured at 400Ex/505Em (Viability) and 
485Ex/520Em (Cytotoxicity) by using Glomax Multi Detection System 
multiwell plate reader (Promega Corporation, USA). After that 100 µl of 
Caspase‐Glo 3/7 reagent was added to each well, and briefly mixed by 
orbital shaking at 300–500 rpm for 30 s and then incubated at room 
temperature for 30–180 min. Luminescence was measured using a Glomax 
Multi Detection System multiwell plate reader (Promega Corporation, 
USA) by Luminescence protocol which is proportional to the amount of 
caspase activity present. 
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5.6 Western Blot analysis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis and Western 
blot analysis were performed on CpHV‐1 infected neoplastic cells and on 
mock infected neoplastic cells. HeLa, U2OS, MDAMB-468, A549, PC3 
and k562 cells in 75 cm2 flask, at confluency, were infected with CpHV‐1 
at MOI 2.5. At 12, 24, and 48 h post‐infection, adherent cells were washed 
twice with PBS and scraped, while K562 suspension cells were collected 
and washed with PBS. Cells were then mixed with cells previously 
collected by centrifugation from supernatant of the same flask and 
resuspended in PBS. While K562 suspension cells were collected and 
washed with PBS. The pellets, obtained by centrifugation, were stored at 
20°C and then processed by Western blot analysis as previouslydescribed 
(Montagnaro S, et al.; 2013). To measure caspases activation at least 
1x106 cells were used. Cells were homogenized directly into lysis buffer 
50 mM Tris pH 7.5; 150 mM NaCl; 1 mM EDTA; 0.25% deoxycholic 
acid, 1% Triton X‐100) with 20 mM sodium pyrophosphate, 0.1 mg/mL 
aprotinin, 2 mM phenylmethylsulphony fluoride (PMSF), 10 mM sodium 
orthovanadate (Na2VO3), and 50 mM sodium fluoride (NaF). Protein 
concentrations were determined by a protein assay kit (Bio‐Rad 
Laboratories). Equal amounts of lysate samples were boiled, loaded on 
bis/acrylamide gels, separated by electrophoresis and proteins were blotted 
from the gel onto PVDF membranes. The membranes were blocked with 
5% nonfat dry milk in Tris buffered saline (TBS: 12.5 mM Tris–HCl pH 
7.4; 125 mM NaCl) at room temperature, washed with TBS‐0.1% Tween 
and incubated with primary antibody. The primary antibodies used were 
rabbit anti‐cleaved caspase 3 (Cell Signaling Technologies catalog no. 
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9662; 1:1,000 diluition), anti-LC3I/II (Cell Signaling Technologies catalog 
no. 4108; 1:1000 diluition) and anti-SQSTM1/p62 (Cell Signaling 
Technologies catalog no. 5114; 1:1000 diluition). After appropriate 
washing steps, peroxidase‐conjugated anti‐rabbit IgG (GE Healtcare, UK, 
catalog no. NA934) (GE Healtcare, UK, catalog no. NA931) was applied 
for 1h at 1:1000 dilution. The blots were stripped and reprobed against 
mouse anti‐actin antibody (Calbiochem, San Diego, CA; catalog no. CP10) 
at 1:2000 dilution to confirm equal loading of proteins in each lane. 
Protein expression levels were quantitatively estimated by densitometry 
using a Gel Doc scanner (BioRad) equipped with a densitometric work 
station. The protein concentrations were normalized to the actin level and 
expressed as relative band density (arbitrary units). 
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6. Results  
6.1 CpHV-1 lytic capacity in various cancer human cell types 
Unlike many herpesviruses, CpHV-1 has a restricted host range and is 
unable to productively infect humans, despite its similarities with HSV-1. 
Before investigating the oncolytic capacity of CpHV-1, we first assessed 
the capacity of virus to induce CPE in a panel of human cancer cells from 
multiple histological origins. As shown in Figure 13, at 24h post infection 
CPE was observed in different cell lines (PC3, MDA-MB-468, U2OS and 
HELA) in wich more than 50% CPE was observed at MOIs comprised 
between 2.5 and 10; MDBK cell line have shown 50% CPE at MOIs 2,5, 5 
and 10. Finally, in A549 cell line we have observed less than 50% CPE 
only at MOI 10.  As shown in Figure 14, at 48h post infection we have 
observed more than 50% CPE in PC3, MDA-MB-468, U2OS, and MDBK 
at MOIs 1, 2,5, 5 and 10; in HeLa cell line we have observed more than 
50% CPE between MOIs 0,5 and 10, while in A549 cell line there was 
50% CPE at MOIs 5 and 10. Otherwise in K562 suspension cells we did 
not observe a decrease in number of living cells by Trypan blue assay (data 
not showed). These data suggest that CpHV-1 has the capacity to induce 
CPE in all adherent human cancer cell line used. 
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Figure 13. Permissiveness of immortalized human cancer cell lines to Caprine 
Herpesvirus 1 (CpHV-1). Cells were infected with the indicated MOI of CpHV-1 and 24h 
post infection, cell monolayers were stained with Giemsa to observe and score Cytopathic 
effect (CPE): +++ indicates very permissive cells, in wich more than 50% CPE was seen; 
++ indicates a moderately permissive cell type, in wich 50% CPE was seen; + indicates a 
cell type that is not very permissive, in wich less tna 50% CPE was seen; - indicates a 
non-permissive cell type, in wich no CPE was observed.  
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Figure 14. Permissiveness of immortalized human cancer cell lines to Caprine 
Herpesvirus 1 (CpHV-1). Cells were infected with the indicated MOI of CpHV-1 and 48h 
post infection, cell monolayers were stained with Giemsa to observe and score Cytopathic 
effect (CPE): +++ indicates very permissive cells, in wich more than 50% CPE was seen; 
++ indicates a moderately permissive cell type, in wich 50% CPE was seen; + indicates a 
cell type that is not very permissive, in wich less tna 50% CPE was seen; - indicates a 
non-permissive cell type, in wich no CPE was observed. 
 
 6.2 Viability 
Infection of seven human cancer cells with the CpHV-1 resulted in cell 
death in a time-dependent and dose-dependent manner, as detected by 
MTT assay (Figure 15). All cell lines, except A549 and K562 cells, 
showed a marked cytopathic effect (CPE), demonstrating an oncolytic 
potential of CpHV-1 in tested human cancer cells. In different cell lines, 
infected at various m.o.i., the decrease of viability appeared 24h and/or 
48h post-infection. In particular, in MDA-MB-468 the viability started to 
decrease at 24h post infection until showing a reduction at 72h post 
infection; U2OS showed only a remarkable decrease of viability at 72h 
post infection; in PC3 we have observed an irregular trend, characterized 
by a reduction of viability at 48h post infection followed by an increase at 
72h post infection. The same trend was observed in HeLa cell line which 
showed a decrease of viability observed at 24h and 48h post infection, 
while presenting an increase of viability at 72h post infection. In MDBK 
cell line we have observed a time and dose dependent decrease of viability 
from 24h to 72h post infection; in A549 cell line we did not have observed 
a significant decrease of viability. Finally, K562 cell line have showed 
increased viability at 24h, 48h and 72h post infection.  
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Figure 15. Dose–response curve of human cancer cell lines infected with different MOI of 
CpHV-1 and observed at different time on cell viability. Viable cells were stained with 
MTT at different hours post infection and the absorbance assayed as described in the 
Materials and Methods Section. Data are presented as a percentage of the control, and 
results are expressed as the mean SE of three independent experiments performed in 
duplicate. Significant differences between control and TCDD-exposed groups are 
indicated by probability P. *P < 0.05, **P < 0.01, and ***P < 0.001. 
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6.3 Time course of virus production and viral expression  
We next determined whether cell death was related to a significant level of 
viral production. For this purpose, infection of CpHV-1-infected human 
cancer cell lines was evaluated as TCID50. Figure 16 shows a time course 
of virus yield, in supernatants and cell associated virus, following exposure 
to CpHV-1 for 24, 48 and 72h at a MOI 2.5. MDBK cell lines was used as 
control. The acme of viral production was observed at 24h post infection in 
MDA-MB-468 (108 TCID50/ ml) and HeLa (107 TCID50/ ml) cells and 
in PC3 (108 TCID50/ ml) cells at 48h post infection. The higher viral titres 
were observed, as expected, in MDBK (1015 TCID50/ ml) at 24h post 
infection. There was no efficient viral replication was in A549 cell line. 
Surprisingly, we have observed a very high viral titre in K562 (1010 
TCID50/ ml) at 48h post infection. Conversely, U2OS and A549 showed 
low viral titres (105 TCID50/ ml, 103 TCID50/ ml respectively).  
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Figure 16. Time course of virus production and cell death in Human cancer cell lines 
infected with CpHV-1. Virus production was titrated at 24, 48 and 72h after infection with 
CpHV-1 at a MOI. of 2.5. Results are expressed as Mean SD of three. 
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6.4 Apotox‐glo™ triplex assay 
We have analysed the effect of CpHV‐1 infection on cytotoxicity, 
viability, and apoptosis within a single assay well, by using the 
ApoTox‐Glo™Triplex assay. The graphs in Figure 17 depicts the results of 
an ApoTox‐Glo™Triplex assay showing the cytotoxicity, viability, and 
apoptosis of HeLa, U2OS, MDAMB-468, A549, PC3, K562 and MDBK 
cells infected with CpHV‐1 at MOI 2.5 at 24h post infection. As showed in 
Panel A, after 24h post‐infection, the cytotoxicity increased significantly 
only in U2OS cell line, compared to mock infected cells. 
 Panel B depicts the results of an Apo‐Tox‐Glo™ Triplex assay showing 
the viability of cells lines infected with CpHV‐1 at MOI 2.5. After 24h 
post‐infection, the viability CpHV‐1 infected cells decreased respect to 
untreated control cells and was considered significant only in U2OS cell 
line compared to mock infected cells.  
Panel C shows the results of an Apo‐Tox‐Glo™ Triplex assay showing the 
activation of caspase 3 in human cancer cell line infected with CpHV‐1 at 
MOI 2.5 at 24h post‐infection. CpHV‐1 infected cells showed significant 
level of caspase 3 at 24h post‐infection in PC3 and U2OS cells respect to 
mock infected control cells.  
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Panel A 
 
 
 
 
 
 
 
   
 
 
Panel B 
 
 
 
 
 
 
 
 
 
 
Panel C 
 
 
 
Figure 17. CpHV‐1 induce apoptosis in human cancer cell lines. Replicate cultures of 
human cancer cell lines were mock infected or infected with CpHV-1 at MOI 2.5. At 24h 
after infection, the cytotoxicity (Panel A), viability (Panel B) and apoptosis (Panel C) 
were assayed using ApoTox‐Glo™Triplex assay. Results are expressed as Relative 
Fluorescence Units (RFU) and Relative Luminescence Units (RLU) and reported as the 
mean SD of three separate experiments. A P‐value <0.05 was selected as significant. 
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6.5 Western blot analysis  
To investigate the modulation of apoptotic pathway in PC3, HeLa, MDA-
MB-468, U2OS, K562 and in MDBK cell lines infected with CpHV‐1, we 
also measured the cleaved form of caspase 3 expression, as apoptotic 
marker, by Western blot analysis. Activation of the DNase responsible for 
oligonucleosomal degradation of nuclear chromatin is dependent on 
cleavage of an inhibitor complexed with the DNase molecule (Sakahira et 
al.; 1998). The cleavage is mediated by caspase‐3. A cleaved caspase‐3 
fragment corresponding to the 17‐kDa protein band was detected at 12h 
post‐infection in MDA-MB-468, U2OS cell lines (Figure 18). Instead, 
cleaved caspase 3 fragment was detected at 24 and 48h post infection in 
PC3 and K562 respectively (Figure 19 and Figure 20). Finally, we have 
investigated the activation of autophagic flow by analyzing the conversion 
of LC3I to LC3II and the simultaneous reduction of protein p62 (Figure 
21). The decrease of LC3I, the increase of LC3II, and the reduction of p62 
were observed only in K562 cells, the other cell lines did not show typical 
pathway of autophagy activation.   
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Figure 18. Caspases activation is induced in PC3, HeLa, MDA-MB-468, U2OS, K562 
and in MDBK cell lines cells infected with CpHV‐1. Replicate cultures of human cancer 
cell lines were mock infected or infected with CpHV-1 at MOI 2.5. At 12h after infection, 
cells were scraped, harvested, lysate, and subjected to Western blot analysis with 
antibodies against Actin and Caspase 3. Actin protein levels were detected to ensure 
equal protein loading. Densitometric analysis of blots relative to Caspase 3. Results are 
expressed as the mean SD of three separate experiments, a P‐value <0.05 was selected as 
significant. 
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Figure 19. Caspases activation is induced in PC3, HeLa, MDA-MB-468, U2OS, K562 
and in MDBK cell lines cells infected with CpHV‐1. Replicate cultures of human cancer 
cell lines were mock infected or infected with CpHV-1 at MOI 2.5. At 24h after infection, 
cells were scraped, harvested, lysate, and subjected to Western blot analysis with 
antibodies against Actin and Caspase 3. Actin protein levels were detected to ensure 
equal protein loading. Densitometric analysis of blots relative to Caspase 3. Results are 
expressed as the mean SD of three separate experiments, a P‐value <0.05 was selected as 
significant. 
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Figure 20. Caspases activation is induced in PC3, HeLa, MDA-MB-468, U2OS, K562 
and in MDBK cell lines cells infected with CpHV‐1. Replicate cultures of human cancer 
cell lines were mock infected or infected with CpHV-1 at MOI 2.5. At 48h after infection, 
cells were scraped, harvested, lysate, and subjected to Western blot analysis with 
antibodies against Actin and Caspase 3. Actin protein levels were detected to ensure 
equal protein loading. Densitometric analysis of blots relative to Caspase 3. Results are 
expressed as the mean SD of three separate experiments, a P‐value <0.05 was selected as 
significant. 
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Figure 21. Autophagy activation in PC3, HeLa, MDA-MB-468, U2OS, K562 and in 
MDBK cell lines cells infected with CpHV‐1. Replicate cultures of human cancer cell 
lines were mock infected or infected with CpHV-1 at MOI 2.5. At 24h after infection, cells 
were scraped, harvested, lysate, and subjected to Western blot analysis with antibodies 
against actin, LC3II and p62. Actin protein levels were detected to ensure equal protein 
loading. Densitometric analysis of blots relative to LC3II and p62. Results are expressed 
as the mean SD of three separate experiments, a P‐value <0.05 was selected as 
significant.
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7. Discussions 
Oncolytic viruses show the natural propensity to infect and kill malignant 
cells, leaving surrounding cells unharmed. Several oncolytic viruses have 
been shown to replicate preferentially in cancer cells (Kelly et al.; 2007; 
Bartlett et al.; 2013). Cancer cells evolve to resist apoptosis and growth 
suppression, evade immune mediated destruction and proliferate 
indefinitely (Nguyen et al.; 2008; Su et al.; 2015; Vähä-Koskela et al.; 
2007); moreover, they have defects in host antiviral response pathways, 
mainly the interferon pathway, which makes these cells unable to 
efficiently fight and suppress viral replication. OVs offer many potential 
advantages over conventional cancer therapies, including the safety, the 
ability of oncolytic viruses to also function as tumour vaccines and to work 
in synergy with conventional cancer therapy (Cervantes-Garcia et al.; 
2008; Li et al.; 2008; Rodrigues et al.; 2010; Vaha-Koskela et al.; 2007). 
Nonhuman wildtype oncolytic viruses show many advantages over human 
vectors, like the incapacity to induce infection in humans and the absence 
of pre-existing immunity (De Munck et al.; 2017; Filley et al.; 2017).  
Thus, in the present study we have investigated the CpHV-1 oncolytic 
potential on a panel of human cancer cells. In a first part of the study, we 
demonstrated that CpHV-1 is able to induce CPE in PC3, MDA-MB-468, 
U2OS, HeLa. Otherwise, A549 and K562 cell lines showed low 
permissiveness to CpHV-1 infection. The same trend was observed in 
cytotoxicity assay experiments. 
Virus growth assays in cancer cell lines demonstrated that CpHV-1 grows 
to a higher titre in PC3, MDA-MB-468, HeLa, U2Os and K562 but not in 
A549 cancer cell. These data confirmed that a reduction in viability 
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corresponded to an increase in viral replication, suggesting the 
permissiveness of infected cell lines.  
These results agree to the data reported in previous studies, which 
demonstrated the permissiveness of PC3, U2OS and MDA-MB.468 cell 
lines to oncolytic BHV-1 (Rodrigues et al.; 2010), a genetically related 
alphaherpevirus. Several other Herpesviruses have been evaluated as 
oncolytic viruses, enclosing Herpes simplex virus type 1 (Dharmadhikari 
N, et al.; 2015), Bovine herpesvirus 1 (Rodrigues et al.; 2010), Bovine 
herpesvirus 4 (a Gammaherpesvirus of the genus Rhadinovirus) (Gillet et 
al.; 2005). Given the genetic similarity between BHV-1 and CpHV-1, we 
believe that CpHV-1 could offer advantageous properties that make it a 
potential new member in the collection of anticancer agents. CpHV-1 is a 
non-pathogenic virus for humans but seems to be able to replicate, with 
production of viral progeny, and kill different human cancer cell lines. The 
virus has a short, defined growth cycle that results in the death of infected 
cells and the virus can be grown to high titres. Another attractive feature of 
CpHV-1 as oncolytic virus is the absence of pre-existing immunity against 
the virus. This would consent the entry of CpHV-1 into human cancer cells 
and consequent replication and spread of the virus that would not be 
delayed by pre-existing antibodies or memory cytotoxic T cells. Moreover, 
CpHV-1 is a large virus and therefore has a wide packaging capacity. This 
feature would allow relatively easy insertion of therapeutic genes that 
could act to increase the oncolytic or the selective properties of an CpHV-1 
oncolytic vector. 
In our experiments, in order to elucidate the mechanism of cell death 
involved in the CpHV-1 oncolytic activity, we have investigated the ability 
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to induce apoptosis. Our experiments have demonstrated the activation of 
apoptotic process in MDA-MB-468 at 12h, 24h and 48h post infection, in 
U2OS at 12h and 24h post infection and in PC3 at 48h post infection. 
These results are in accordance with the decrease of viability and the high 
viral titres in these cell lines, confirming the ability of the virus to induce 
apoptosis. This is consistent with our previous studies which demonstrated 
that, CpHV-1 during lytic cycle exert its replicative potential inducing 
apoptosis in ruminant epithelial cells, in peripheral blood mononuclear 
cells and in a murine neuroblastoma cell line (Longo et al.; 2009; 
Montagnaro et al.; 2013) and agree with the results obtained by Cardoso et 
coll., who has demonstrated that oncolytic potential of BHV-1 is mediated 
by apoptosis induction in and glial-derived tumor cell cultures (Cardoso et 
al.; 2016). 
As expected, we did not observe the activation of apoptotic process in 
A549 and this aspect is in line with the increase of cell viability and the 
weak viral yield observed in these CpHV-1 infected cells.  In HeLa cells 
we didn’t observe caspase 3 activation despite of the relatively high viral 
titre detected. Surprisingly, in K562 cell line we observed the caspase 3 
activation at 48h post infection related to a high viral titre despite a low 
cytotoxicity and it is noteworthy that in K562 a very high viral titre was 
detected in presence of a significant increase of cell viability. Moreover, 
we showed that in CpHV-1 infected K562 cells an accumulation of the 
autophagosome-associated form of LC3, a marker of autophagy activation. 
The modification of LC3 correlated with increased formation of 
autophagosomes, with cytoplasmic depletion and with degradation of the 
autophagy marker p62/SQSTM1 polyubiquitin binding protein. Our results 
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are in agreement with other studies about herpesviruses. Infact, Takahashi 
et coll. (2009) have demonstrated that VZV infections induces autophagy 
in permissive cancer cells line at late stage of infection with depletion of 
p62. It was also demonstrated that HSV-1 infection induces autophagy in 
macrophages (English et al.; 2009).  
Modulation of autophagy affords great advantages to the virus, facilitating 
virus replication, the spreading of progeny virus to neighbouring cells and 
providing the protection for the progeny virus against cellular enzymes 
(Deretic and Levine; 2009; Cavignac and Esclatine; 2010). Autophagy 
protects host cells against viral attack by degrading the viruses in 
autolysosomes, or by activating the innate immunity of the cells by loading 
viral components onto endosomal sensors such as TLRs (Talloczy et al.; 
2006; Delgado et al.; 2008). It has been suggested that autophagy may 
have a deleterious effect on viral pathogenesis in the case of the 
neurotropic Sindbis virus (Liang et al.; 1998), and the role of autophagy 
has been clearly demonstrated to limit the replication of the tobacco 
mosaic virus (Liu et al.; 2005). Then, despite the ability of autophagy to 
function as an anti-viral mechanism, some viruses appear to up-regulate 
the process and/or subvert autophagic genes in order to enhance their 
replication (Kudchodkar et al.; 2009).  
Deregulation of autophagy is implicated in several human diseases 
including cancers. Several studies have shown that tumour cells are 
defective in autophagy and/or apoptosis pathway (Chen et al.; 2009). 
Autophagy may protect against cancer by isolating damaged organelles, 
allowing cell differentiation, increasing protein catabolism, and even 
promoting cancer cell death. Autophagy-defective tumour cells also 
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display elevated genome damage with stress, suggesting that damage 
mitigation by autophagy is a cell-autonomous mechanism of tumour 
suppression (Karantza-Wadsworth et al.; 2007; Mathew et al.; 2007a, b). 
Several studies found that induction of autophagy may be a viable new 
therapeutic arm in fighting cancer. Although our findings have shown that 
the CpHV-1 was not able to kill K562 cells, it was able to induce the 
apoptosis and autophagy activation, restoring the defective pathways. It 
was demonstrated that that by introducing the Beclin-1 gene into the 
oncolytic adenoviral backbone, the antileukemia activity of the virus on 
multidrug-resistant cell lines can be significantly improved (Li et al.; 2014; 
Zhang et al.; 2006). These results could suggest that targeting the 
autophagic cell death pathway by CpHV-1 may represent a novel strategy 
for gene virotherapy, above all for combination with conventional cancer 
therapies and for chemotherapy resistance.   
Several aspects of the CpHV-1-mediated cell death in neoplastic cells 
reported herein need to be addressed with further experimentation. In 
particular, the activation of intrinsic or extrinsic pathway of apoptosis, the 
role of INF in virus infection and the mechanism responsible for induction 
of autophagy in CpHV-1 infection as well as the impact of the CpHV-1 as 
oncolytic virus remains to be identified. These issues are currently under 
investigation in our laboratory. 
Overall, in conclusion, our findings showed that CpHV-1 replicates and 
decreases the viability in several human cancer cells; furthermore, it 
induces apoptosis and the activation of autophagy pathway and it could 
represent a new candidate for the oncolytic virus immunotherapy.
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